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In this work, the processing and manufacturing of co-crystals have been investigated for two 
systems of sulfamethazine (SMT), with respective coformers, salicylic acid (SA) and 3-
methylsalicylic acid (3mSA), both in 1:1 stoichiometry. Slurry conversion crystallization is 
demonstrated as a successful route for the manufacture of pure co-crystal. This technique 
involves equilibrating the solid co-crystal components and solvent in a specific ratio at a certain 
temperature. In any solvent, guided by the ternary phase diagram, as long as the overall 
composition is in the region where co-crystal is the most stable solid phase, pure co-crystal can 
be obtained by this technique. 
The phase diagrams for these co-crystals have been determined and analyzed in different 
solvents and at different temperatures. For model system 1, 1:1 SMT-SA co-crystal, ternary 
phase diagrams in three solvents- methanol, acetonitrile and 7:3 (v/v) dimethylsulfoxide 
(DMSO)-methanol mixture, and at three temperatures were constructed. For model system 2, 
1:1 SMT-3mSA, phase diagrams in methanol and acetonitrile, at 30 oC were constructed. SMT-
3mSA formed a new co-crystal wherein its crystal structure was solved and it was thoroughly 
characterized. The SMT-SA co-crystal showed congruent dissolution in acetonitrile but 
dissolved incongruently in the other two solvents, whereas the SMT-3mSA co-crystal showed 
incongruent dissolution in both methanol and acetonitrile. The choice of solvent is shown to 
have a strong impact on the appearance of the ternary phase diagram and affects the dissolution 
behavior of the co-crystal, significantly. Temperature did not show a significant effect in the 20 
oC temperature range studied for SMT-SA co-crystal. The thermodynamics of both the co-
crystals were investigated. The values for Gibbs energy of co-crystal formation were negative 
signifying the thermodynamic stability of the co-crystal over a mixture of pure components. A 
relation between the size of the region where the co-crystal is the stable solid phase in the 
ternary phase diagram and the relative solubility (solubility ratio) of coformer to API was 
uncovered. 
SMT was found to form solvates with three solvents- dimethylsulfoxide, N,N-
dimethylacetamide and N,N-dimethylformamide, all in 1:1 stoichiometry. The solvates were 
characterized by various analytical techniques and their solubility was determined in their 
respective solvents at 25 oC. The solubility of the solvates was much higher than the solubility 
of SMT in common solvents like water and methanol. Desolvation experiments produced the 
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monomorphic pure crystalline SMT. The desolvation temperature and the enthalpy of 
desolvation were much lower than the melting temperature and the enthalpy of vaporization of 
the pure solvent, respectively, suggesting weaker bonding in the solvates than in pure solvents. 
Microwave-assisted slurry conversion for co-crystal manufacture was evaluated and compared 
to conventional slurry crystallization at same temperature keeping other conditions identical. 
Microwave technique not only increased the rate of co-crystal formation but also proved to be 
scalable at least up to 20 g. Three new co-crystals, SMT-nicotinamide, sulfamerazine (SMR)-
anthranilic acid and SMR-salicylamide were discovered and characterized thoroughly. The co-
crystals increased the equilibrium concentration of drug in solution as compared to pure APIs. 
A difference in stability, reactivity and rate of co-crystal formation between the two sulfa drugs 
was observed and discussed via Hirshfeld analysis and interaction energy calculations.   
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Chapter 1. Introduction and Aim of the Project 
1.1 Background 
The active pharmaceutical ingredient (API) is a key component of a drug product. One of the 
major challenges in the pharmaceutical industry is the low solubility of the APIs, as many drugs 
fall in the Biopharmaceutical Classification System (BCS) Class II.1-3 BCS is a scientific system 
that classifies APIs into four groups, based on in-vitro drug dissolution and in-vivo 
bioavailability representing solubility and gastrointestinal permeability (See Figure 1.1).4 If the 
highest dose of the API is soluble in 250 mL or less of aqueous media over the pH range of 1.0 
- 7.5, the drug is regarded highly soluble, else it is considered poorly soluble. When the extent 
of absorption is higher than 90 % of the administered dose,  it becomes a highly permeable drug 
substance; else it is deemed as a poorly permeable drug.5  
 
Figure 1.1. The Biopharmaceutical Classification System (BCS).2  
Several challenges associated with poorly soluble APIs include low and erratic bioavailability, 
slow dissolution, sub-optimal therapeutic effects, and increased drug development costs.6-8 
Pharmaceutical scientists are always on a lookout for new opportunities and methods to 
improve the pharmacokinetics of poorly soluble APIs by synthesizing diverse solid forms with 
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an apt balance of the key physicochemical properties like solubility, compressibility, stability, 
dissolution, hygroscopicity and bioavailability. 
To modify the properties, both amorphous and crystalline solid forms have been developed. 
Both strategies have their advantages and can profoundly influence the properties of the drug. 
However, there is no universal strategy applicable to all drugs. Amorphous materials possess a 
random atomic structure and a short-range molecular order. An important property of the 
amorphous materials is their high solubility as compared to their crystalline counterparts. 
However, stability is a serious concern associated with the development of amorphous drugs. 
Crystalline materials obtain their fundamental physicochemical properties from the crystal 
packing of molecules or ions within the solid and varying the placement or interactions between 
the molecules directly influences the properties of the particular solid. Generally, crystalline 
solids are preferred for their ability to satisfy the stability, purity and processing specifications.9 
They are further classified as single component or multi-component solids (Figure 1.2). 
Polymorphism serves to modulate the physicochemical properties of single-component solids. 
It is the ability of a crystalline compound to exist in different molecular arrangements, called 
crystalline forms.10, 11 Contrary to this, multi-component crystalline solids can be 
stoichiometric/non-stoichiometric and include hydrates, solvates, salts, solid solutions, 
inclusion compounds and co-crystals providing ample prospects to tailor the physicochemical 
properties. All solid forms have their own challenges, as in the case of solvates, hydrates and 
inclusion compounds, physical stability can be an issue, and salts are restricted to active 
pharmaceutical ingredients having ionisable moieties. 
Co-crystals are recognized as a potent and feasible addition to the above-mentioned traditional 
methodologies to alter the physicochemical properties of materials. The interest in the new multi-
component systems, especially co-crystals can be recognized by the increasing number of new 




Figure 1.2. Possible crystalline forms for an API: (a) and (b) polymorphs; (c) solvate/hydrate; 
(d) salt; (e) molecular co-crystal; (f) ionic co-crystal; (g) nonstoichiometric inclusion 
compounds including channel hydrates, solvates; (h) solid solutions (mixed crystals).9  
Broadly, co-crystals are defined as crystalline molecular complexes comprising two or more 
neutral components that in the pure state are solid at room temperature. The molecules in a co-
crystal interact by non-covalent interactions, especially hydrogen bonding. Co-crystallization 
brings about changes in the crystal structure for the API, hence altering the physical properties. 
Lack of any new covalent bonding keeps the chemical structure the same.9, 13, 14 A lot of research 
has been focused on finding new co-crystals and rationalizing their formation. There are limited 
studies in the literature on their physical properties, how they change with coformer, their 
thermodynamic aspects as well as processing.15-17 A detailed phase diagram highlights the 
stability of co-crystal as a function of the concentration of the API and coformer in solution, 
based on which a crystallization process for co-crystal manufacture can be designed.18-20 
Literature reports a number of ternary phase diagrams of co-crystals, and some study the effect 
of temperature and solvent.21-23 However, the factors that control the appearance of the phase 
diagrams, cause co-crystal dissolution to be congruent or incongruent, and control the size of 
4 
 
the co-crystal stability region in the phase diagram are not understood. A co-crystal is said to 
show congruent dissolution when it can establish an equilibrium with a solution of 
stoichiometric composition. However, when a co-crystal transforms into another solid phase 
and the equilibrium solution is not stoichiometric in composition, it is known as incongruent 
dissolution.  
Solvates are multi-component crystalline solids in which solvent is present in stoichiometric or 
non-stoichiometric amounts. Exposure of APIs to solvent or solvent vapour during industrial 
processing, manufacturing or storage can lead to the formation of solvates/hydrates as most 
APIs possess a variety of functional groups.24, 25 Small molecular size, presence of both 
hydrogen bond donor and acceptor groups and atmospheric humidity cause a high 
possibility of hydrate formation. Since solvate formation changes the crystal structure of 
the API, they show different physical properties, especially stability.26 Nonetheless, some 
solvates possess the capability to improve the physicochemical properties of drugs and can be 
considered in particular cases, especially for high potent low dosage drugs.27-29 Hence, 
characterization of solvates is of significant importance as their presence can impart a 
characteristic physicochemical property to the API and influence on manufacturing on the 
particular desired form.30, 31 Additionally, desolvation of solvates may provide a route to access 
novel forms of an API, which might be inaccessible by the conventional crystallization 
technique.32-34 
1.2 Scope of the Project 
The focus of this work was to develop an understanding of manufacturing and processing co-
crystals, and to investigate their phase diagram aspects. Slurry conversion crystallization was 
investigated for co-crystal manufacture, in different solvents and for systems with both 
congruent and incongruent dissolution behaviour.  
The thermodynamics and crystallization of the co-crystals were investigated by constructing 
their ternary phase diagrams in different solvents and at different temperatures. The objectives 
include identifying the stability regions of the co-crystal in different solvent systems; studying 
the effect of pure component solubility and temperature on the appearance, shape, and 
symmetry of the phase diagrams; study the stability of co-crystals in terms of key 
thermodynamic parameters, Gibbs energy, enthalpy and entropy. For this, two co-crystals for 
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the model API, sulfamethazine, were chosen with the coformers, salicylic acid and 3-
methylsalicylic acid, both co-crystals in 1:1 stoichiometry. 
In the process of solvent selection for phase diagram construction, sulfamethazine was found 
to form solvates with a few solvents. Due to the importance of solvates to the pharmaceutical 
industry, and their possible formation during API exposure to solvent, the solvate formation 
ability for sulfamethazine was investigated. 
Microwave assisted slurry conversion was examined and compared to conventional slurry 
conversion for co-crystal manufacture. Co-crystals of two sulfonamide drugs, sulfamethazine 
and sulfamerazine were used as models. 
1.3 Thesis Chapter Outline 
‘Chapter 1’ gives the introduction, a brief background on the research topic and discusses the 
aims of the project. 
‘Chapter 2’ discusses the theory and literature review on the topic of interest.  
‘Chapter 3’ outlines the material and equipment used to carry out the research. 
‘Chapter 4’ investigates the solid-liquid phase diagrams of sulfamethazine-salicylic co-crystal, 
studies the impact of solvent and temperature on the appearance of ternary phase diagrams, co-
crystal dissolution behaviour, and discusses co-crystal stability in terms of thermodynamic 
parameters like Gibbs energy, enthalpy and entropy.  
‘Chapter 5’ discusses the solvate formation ability of the API, sulfamethazine with three 
solvents, their characterization by various analytical techniques and their solubility. 
‘Chapter 6’ investigates solid-liquid phase equilibria and ternary phase diagrams for a new co-
crystal sulfamethazine-3-methylsalicylic acid and performs similar studies as mentioned in 
Chapter 4. 
‘Chapter 7’ evaluates the microwave-assisted slurry conversion crystallization for 
manufacturing co-crystals of sulfamethazine and sulfamerazine, and compares it to the simple 
heating. 
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Chapter 2. Theory and Literature Review 
2.1 Crystallization and Solid State 
Crystallization is defined as a process of phase change in which a solid crystalline product is 
obtained from solution, melt or directly from gas phase.1, 2 It has been used for the separation, 
isolation and purification for a very long time.3 This technique is particularly important to the 
pharmaceutical industry for the manufacture of APIs.4, 5 It is a two-step process involving 
nucleation and crystal growth. Nucleation refers to the formation of a new phase in which a 
small number of ions, atoms or molecules come together and form an arranged pattern held 
together by intermolecular forces. Crystal growth is described as a process, which causes the 
pre-existing particles to increase in size by the progressive addition of atoms or molecules. A 
solution with the maximum amount of dissolved solute at a certain temperature, is called a 
saturated system. At this stage, the system is at equilibrium, i.e. the chemical potential of the 
solute in the solution equals the chemical potential in the solid phase. Despite numerous 
crystallization studies in the literature, the fundamental principles of crystallization are not fully 
understood, as this phenomenon is complicated and unique to each molecule. 
Solids can exist as crystalline or amorphous forms. A crystalline solid or a crystal is a material 
whose constituents i.e. atoms, ions or molecules are arranged in a long-range ordered 
macroscopic structure, forming a lattice that extends in all directions.6 The smallest repeating 
defined structural unit of symmetry within a crystalline lattice is called a unit cell, which is fully 
described by six lattice parameters, including the three axial lengths (a, b, c) and three inter-
axial angles (α, β, γ). There are 7 crystal systems and 14 Bravais lattices for different 
magnitudes of the lattice parameters based on geometrical shape and symmetry (Figure 2.1). 
They are distinguished from amorphous solids by having a representative unit of structure 
repeated in space at regular intervals on a periodic array of points called a lattice.7 Amorphous 
solids have a random atomic or molecular arrangement structure and only a short range order. 
Crystalline solids include polymorphs, hydrates, solvates, salts, solid solutions, inclusion 
compounds and co-crystals providing ample prospects to tailor the physicochemical properties 
of the API. They are formed as a result of modifications in the physical arrangement of the 




Figure 2.1. The seven crystal systems based on their unit cell.8  
2.2 Co-crystal 
The history of co-crystals dates back to the 18th century, when a quinhydrone co-crystal was 
reported containing quinone and hydroquinone in 1:1 stoichiometry.9 However, its structure 
was determined only after almost over a century.10 In one of the earliest reports in 1968, the 
term ‘co-crystal’ was used to describe a crystalline molecular complex of pyrimidine and 
purine.11 Inspection of literature published before 2000 suggests the presence of hundreds of 
co-crystals, as summarized by Stahly.12 
The exact definition of the term ‘co-crystal’ has been a matter of discussion and debate. Last 
few years have witnessed a large number of individual contributions to the definition of co-
crystals.13-17 However, they can, in general, be defined as crystalline molecular complexes 
comprising two or more components generally in a stoichiometric ratio and are solid at room 
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temperature. Solvates and hydrates are distinguished from co-crystals by this definition as they 
consist of a solid component interacting with solvent/water molecules (liquid state).   
Co-crystals interact and arrange according to mutual recognition based on the topography of 
coformers. They and are held together by non-covalent interactions like hydrogen bonding, van 
der Waals interactions, or pi-pi interactions. Among these, hydrogen bonding is considered one 
of the most important interactions because of its high directionality and energy. Along with the 
interactions, the pKa rule is often used to predict whether an acid-base pair of compounds will 
crystallize as a salt or a co-crystal. The pKa rule states that ‘Salt formation generally requires a 
difference of at least 3.0 pKa units between the protonated base and the acid i.e. [pKa (base) - 
pKa (acid) ≥ 3.0]’, and a ∆pKa below 0 predicts that the multicomponent crystal most likely 
would be a co-crystal. However, for ∆pKa values between 0 and 3, the prediction is not very 
accurate, and either a salt or a co-crystal may result.18-20 
2.2.1 Importance 
Co-crystals are recognized as a pharmaceutical co-crystal if one of the components is an API 
and the other is a pharmaceutically acceptable coformer. The importance of co-crystallization 
lies in their ability to modify the physicochemical properties of the pure API, without modifying 
its chemical structure. Co-crystal attains a new crystal structure without disturbing any covalent 
bonds of the starting components. There are studies in the literature that report improvement in 
properties like hygroscopicity,21, 22 compressibility,23 stability,23-25 tabletability,22 solubility and 
bioavailability.26-28 Another co-crystal dimension that appeals to the pharmaceutical industry is 
patentability as they provide a new form of the existing API, which can offer enhanced 
properties. 
The interest in new co-crystals can be realized by the increasing number of new entries in the 
Cambridge Structural Database.29 Sulfa drugs are multi-functional i.e. they possess a variety of 
hydrogen bond donors and acceptors, making them able to form a large number of co-crystals.30-
32 There are 32 co-crystals and co-crystal solvates for sulfamethazine (SMT) and 2 co-crystals 





A variety of methods have been used in the literature to synthesize and screen co-crystals. These 
include solution-based methods like cooling crystallization, evaporation crystallization,31, 33-35, 
reactive crystallization;36 isothermal slurry conversion, solvent-drop grinding37, 38 and solvent-
free methods like mechano-chemical synthesis i.e. dry grinding, twin-screw extrusion.39 Other 
recent techniques include spray drying,40-42 sonication,43-45 supercritical fluid technology46, 47, 
high shear wet granulation,48 co-sublimation,36 laser irradiation,49, and freeze-drying. 
2.2.2.1 Solid based methods 
Mechanochemistry (neat grinding and liquid assisted grinding) is a popular, environment-
friendly technique for manufacturing co-crystals as it does not use any bulk solvent. The process 
of neat grinding involves grinding a mix of the API and coformer in dry solid-state either by a 
mortar and pestle or in a ball mill. However, often this technique does not lead to the formation 
of the co-crystal or the conversion is incomplete.50  
Liquid assisted grinding involves grinding the solids with at least a small amount of solvent, 
and is in general preferred over neat grinding because of its higher efficiency in co-crystal 
formation.51  Grinding can even introduce amorphization, crystal defects and reduce particle 
size.52-54 Scalability is another concern associated with grinding and milling. 
Twin-screw extrusion is a continuous technique for producing co-crystals, however high shear 
and temperature limit the use of components subject to thermal degradation.  
2.2.2.2 Solution-based and methods 
Traditional solution-based techniques are the most popular for industrial crystallization and 
scale-up as they provide an effective purification step and help to control the solid form.55-59 
For congruently dissolving co-crystals, all the solution-based methods can lead to pure co-
crystal formation but for incongruent co-crystal systems, the knowledge of the ternary phase 
diagram may be necessary as pure co-crystal will be obtained only depending on the starting 
composition.60 In congruent dissolution, an equilibrium is established between the solid co-
crystal and a stoichiometric solution. In incongruent dissolution, a change in solid form occurs 
and a non-stoichiometric solution is generated. 
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Cooling or evaporative crystallization is generally employed to generate single crystals for 
crystal structure elucidation. This requires preparing a saturated solution containing both co-
crystal components, followed by lowering the temperature of the solution or by evaporation of 
the solvent to generate supersaturation with respect to the co-crystal. There are numerous 
examples in the literature that use these methodologies to harvest co-crystal single crystals.61, 
62  
An important technique for co-crystal synthesis is isothermal slurry conversion crystallization. 
This involves adding starting components i.e. the API and the coformer in excess of solubility 
and equilibrating them with the solvent at a fixed temperature for a certain time. Croker and 
Rasmuson have shown the efficacy of this technique for p-toluene sulfonamide-
triphenylphosphine oxide co-crystal, which shows stoichiometric diversity existing in 1:1 and 
3:2 stoichiometry.60 Coupling isothermal slurry conversion with microwaves for co-crystal 
synthesis can accelerate the rate of co-crystal formation. Microwaves are electromagnetic 
waves in the frequency range 0.3 to 300 GHz that produce ‘dielectric heating’ on interacting 
with polar and polarizable materials.63 On irradiation, the molecules align and orient themselves 
with the applied electric field, changing direction with the microwave frequency.64 The repeated 
alignment, randomization because of thermal motion and realignment in the opposite direction 
generates molecular friction which translates into heat.65 At a certain frequency and 
temperature, loss tangent (tan 𝛿 = ε’’/ ε’) helps determine the ability of a material to convert 
electromagnetic energy into heat. The dielectric constant, ε’, represents the ability of dielectric 
material to store electrical potential energy under the influence of electric field. The loss factor, 
ε’’, quantifies the efficiency of conversion of absorbed energy into heat. For decades, 
microwave irradiation has been used as a source of energy for synthesis in organic and inorganic 
chemistry.66-68 The use of microwaves in synthetic chemistry started in 1986.69, 70 In 2002 and 
2004, there were reports on the formation of inclusion compounds using microwave heating.71, 
72 In 2008, a loratadine inclusion complex regarded as co-crystal was synthesized by microwave 
irradiation and improvement in solubility and bioavailability was reported.73 In 2013, 1:1 and 
2:1 caffeine - maleic acid co-crystals prepared by microwave method were reported and the 
effect of dielectric properties of solvent on interaction with microwave was shown.64 Co-
crystals of caffeine acid phenethyl ester with improved properties and prepared by microwave 
technique were reported in literature.74 
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2.2.3 Ternary phase diagram 
A phase diagram is a graphical representation depicting the regions of 
temperature/pressure/composition at which particular phases of a chemical system are 
thermodynamically stable at equilibrium.75 Construction of a complete ternary phase diagram 
representing ternary composition and temperature requires a 3-D diagram. This 3-D space 
model is achieved by using a triangular prism, wherein the temperature is plotted on the vertical 
axis and the compositions are represented on the base of the prism, which is an equilateral 
triangle (Figure 2.2). For a ternary system comprising components A, B and C, the sides of the 
prism (triangle) represent the three binary systems, AB, BC, and AC.  
 
Figure 2.2. Space Plot for Ternary Phase Diagram 
Triangular diagrams are isothermal slices for prismatic diagrams, each vertex denoting a 
component (Figure 2.3).  
The Gibbs rule of phases helps in the construction of the phase diagram (see Equation 2.1).76 
Equation 2.1.       𝐹 = 𝐶 − 𝑃 + 2 − 𝑅 
In the phase rule, ‘F’ represents the number of degrees of freedom, specifying the number of 
parameters that can be changed without changing the phases, ‘C’ corresponds to the number of 
individual components and ‘P’ is the number of phases. ‘2’ represents the two external 
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parameters, i.e. temperature and pressure, ‘R’ corresponds to the number of chemical reactions. 
If it’s a non-reacting system, the phase rule becomes Equation 2.2.  
 
Equation 2.2.       𝐹 = 𝐶 − 𝑃 + 2 
For co-crystal phase diagrams, the three components are the API, coformer and solvent, the 
four phases are the liquid (solvent containing variable quantities of API and co-former), the 
crystalline API, co-former and co-crystal. 
Equation 2.3.       𝐹 = 3 + 2 − 𝑃 = 5 − 𝑃 
Under isothermal and isobaric conditions, the number of degrees of freedom is reduced by two, 
called the isothermal variance. 
Equation 2.4.       𝐹′ = 3 − 𝑃 
A typical co-crystal (API-coformer) ternary phase diagram is depicted in Figure 2.3. The point 
‘C’ depicts the solid-state composition of co-crystal. ‘K’ and ‘L’ represent the solubilities of 
pure API and coformer respectively or the solid-liquid equilibrium in the binary system. The 
lines, ‘KI’ and ‘JL’ represent the solubilities of API and coformer as a function of system 
composition. The diagram is divided into several areas with unique phases and compositions. 
The points I and J, called invariants/eutectic points, represent solution concentrations at which 
two solid phases (API + co-crystal, or coformer + co-crystal) are in equilibrium with the same 










1 1 Solid co-crystal in equilibrium with liquid  
2 1 Solid API in equilibrium with liquid 
3 1 Solid coformer in equilibrium with liquid 
4 0 Solid API and solid co-crystal in equilibrium with liquid 
5 0 Solid coformer and solid co-crystal in equilibrium with liquid 
6 2 Homogenous liquid phase containing API and coformer 
 
2.2.4 Thermodynamics of Solid-Liquid Phase Equilibria 
Solubility of a solute is the analytical composition of a saturated solution, expressed in terms 
of the proportion of a designated solute in a designated solvent at a given temperature. Solubility 
represents a thermodynamic equilibrium between the solute in a solution and the solid phase. It 
is a function of temperature, pressure and the solvent. Its importance for pharmaceuticals arises 
from the fact that drugs need to dissolve before they can be absorbed. Since many 
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pharmaceutical drugs suffer from poor aqueous solubility, improvement in solubility is required 
to achieve the therapeutic effect.77  
For a solution in equilibrium with the solid phase, the chemical potential of a solid is equal to 
that of the solute in solution (µsolute) (Equation 2.5). Hence, the activity of the solid is equal to 
that of solute in solution if the same reference state is used for both phases (Equation 2.6). γeq 
and xeq represent the activity coefficient and molar concentration of the solute in the solution at 
equilibrium. The activity coefficient accounts for the deviation from ideal behaviour in a 
mixture of components. 
Equation 2.5. µ𝑠𝑜𝑙𝑖𝑑 = µ𝑠𝑜𝑙𝑢𝑡𝑒 
Equation 2.6. 𝑎𝑠𝑜𝑙𝑖𝑑 = 𝑎𝑠𝑜𝑙𝑢𝑡𝑒 = 𝛾𝑒𝑞𝑥𝑒𝑞 
The chemical potential of the solid, µsolid, is given by Equation 2.7, where µ𝑠𝑜𝑙𝑖𝑑
°  is the chemical 
potential of the thermodynamic reference state, R is the gas constant, a is the activity of the 
solid at temperature T.  
Equation 2.7. µ𝑠𝑜𝑙𝑖𝑑 = µ𝑠𝑜𝑙𝑖𝑑
° + 𝑅𝑇𝑙𝑛𝑎𝑠𝑜𝑙𝑖𝑑 
A 1:1 co-crystal ‘AB’ equilibrates with the API ‘A’ and the coformer ‘B’ in the saturated 
solution as per Equation 2.8. The corresponding equilibrium constant can be expressed in terms 
of thermodynamic activities. The solubility product, Ksp refers to the solubility product of the 
co-crystal, when the activity of the solid co-crystal is taken as unity (Equation 2.9). If the 
reference state is taken as the solid phase itself, the activity becomes unity. Neglecting the 
contributions from activity coefficients (γ), Ksp can be approximated by the product of 
concentrations of its co-crystal components, with concentrations in mol/L. This approximation 
is valid for ideal and dilute solutions. This approximation also neglects the influence of third 
component on the activity coefficient of each component. The co-crystal intrinsic solubility 











Equation 2.9. 𝐾𝑠𝑝 = 𝑎𝐴,𝑙𝑖𝑞𝑎𝐵,𝑙𝑖𝑞 = 𝛾𝐴[𝐴]𝛾𝐵[𝐵]  ≈ [𝐴][𝐵] 
Equation 2.10. 𝑆𝐴𝐵 = √𝐾𝑠𝑝 
2.2.5 Co-crystal formation thermodynamics 
The formation of a 1:1 co-crystal AB from its solid components A and B can be expressed as: 
Equation 2.11. 𝐴(𝑠) + 𝐵(𝑠) → 𝐴𝐵 (𝑠) 
The Gibbs energy change associated with co-crystal formation can be estimated as per Equation 
2.12. 
Equation 2.12. ∆𝐺𝑓 = 𝐺𝐴𝐵 − (𝐺𝐴 + 𝐺𝐵) 
Considering the equilibrium between solid API with its saturated solution, the corresponding 
Gibbs energy for the reaction can be estimated as in Equation 2.13. A similar equation can be 
written for the coformer B (Equation 2.14). These equations assume the activities of the solid 
states to be 1.  
Equation 2.13. 𝐴(𝑠) ↔ 𝐴(𝑙𝑖𝑞); 𝐺𝐴 = −𝑅𝑇𝑙𝑛𝑎𝑙𝑖𝑞
𝐴  
Equation 2.14. 𝐵(𝑠) ↔ 𝐵(𝑙𝑖𝑞); 𝐺𝐵 = −𝑅𝑇𝑙𝑛𝑎𝑙𝑖𝑞
𝐵  
The relation for a solid co-crystal in equilibrium with its components in a saturated solution can 
be written as: 
Equation 2.15. 𝐴𝐵(𝑠) ↔ 𝐴(𝑙𝑖𝑞) + 𝐵(𝑙𝑖𝑞); 𝐺𝐴𝐵 = −𝑅𝑇𝑙𝑛𝑎𝑙𝑖𝑞
𝐴+𝑎𝑙𝑖𝑞
𝐵+ 
Substituting the data from Equation 2.13, 2.14 and 2.16 into 2.12, we get: 












The Gibbs energy of co-crystal formation can be estimated from Equation 2.16.78, 79 𝑎Iⅈq
A+ and 
𝑎Iⅈq
B+denote the activities of the solute in a solution in equilibrium with the pure co-crystal 
components (API and coformer) respectively; 𝑎Iⅈq
𝐴  and 𝑎Iⅈq
𝐵  are the activities of the co-crystal 
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components in a solution in equilibrium with pure co-crystal. If the activities are approximated 
with the concentrations in mol/L, the Gibbs energy change can be estimated.  
Equation 2.17 describes the fundamental equation of chemical thermodynamics that relates 
Gibbs energy, enthalpy and entropy change. A negative Gibbs energy change indicates a stable 
co-crystal in comparison to a physical mixture of components. In a closed system where 
pressure remains constant and no work is added, the change in Gibbs energy with temperature 
is given in Equation 2.18. Gibbs Helmholtz equation (Equation 2.19) and the Maxwell relation 
(Equation 2.18) may be derived from Equation 2.17. 
The enthalpic and the entropic components of the Gibbs energy of co-crystal formation can be 
estimated if there is Gibbs energy data at different temperatures. 





















2.2.6 Factors influencing Phase Diagram 
There are a number of phase diagrams reported in the literature with varied appearances. The 
most important parameters that affect the shape, symmetry, and appearance of the phase 
diagrams include solvent and temperature, causing a co-crystal to dissolve congruently or 
incongruently. Figure 2.4 depicts a schematic of ternary phase diagrams showing congruent and 
incongruent dissolution of co-crystals. For congruent dissolution, the region where co-crystal 
is the stable solid phase is somewhat symmetric and is present on both the left and right hand 
sides of the stoichiometric line in the diagram.60, 80 In such a case, co-crystal dissolution 
generates a solution of stoichiometric composition. In contrast, incongruent dissolution of co-
crystals, leads to formation of another solid phase and the equilibrated solution is not 
stoichiometric. Such a case results in an asymmetric phase diagram. In Figure 2.4b, following 
the 1:1 stoichiometric line in the ternary phase diagram, if the co-crystal is equilibrated with 
the solvent, the solid obtained would either be the API or a mixture of API and co-crystal 
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depending on the extent of dissolution and amount of solvent (Figure 2.4b). If the phase diagram 
is skewed towards coformer, the solid obtained could be either coformer or a mixture or 
coformer and co-crystal. The factors that dictate the co-crystal dissolution behavior are not fully 
understood. Temperature can also lead to varied changes in the appearance of the phase 
diagrams. Increasing the temperature causes the solubility of the solid phases to increase, 
causing the solid-state regions to move towards the API-coformer axis in the ternary phase 
diagram. It is important to understand whether the change is relative as temperature is modified. 
 
Figure 2.4. Schematic showing congruent and incongruent dissolution for co-crystals.  
It is important to understand the co-crystal stability and formation. The best indicators to co-
crystal stability with respect to its pure components is of course the thermodynamic parameter, 
Gibbs energy. In 2006, Nehm et al. developed mathematical models to describe co-crystal 
solubility, considering the equilibria between co-crystals, pure components, and solution 
complexes, and demonstrated its use for carbamazepine-nicotinamide co-crystal.81 They 
described the co-crystal solubility by a solubility product (Ksp). They studied solution 
complexation and found that co-crystal solubility increased if complexation occurred. Chiarella 
et al. constructed ternary phase diagrams for 1:1 trans-cinnamic acid-nicotinamide co-crystal 
in methanol and water and showed solvent dependent congruent and incongruent dissolution.82 
Another contribution by Jayasankar et al. aimed at identifying the factors that affected the 
formation and stability of co-crystals with different stoichiometry.83 A 2:1 co-crystal of 
carbamazepine and 4-aminobenzoic acid existed and 1:1 co-crystal was discovered. Both co-
crystals could be synthesized by reaction crystallization method by varying ligand 
concentration. In a study from 2012, Leyssens and coworkers showed the importance of solvent 
for synthesis and stability of stoichiometrically diverse co-crystals using caffeine-maleic acid 
as the model system.84 In acetone, wherein maleic acid was 40 times more soluble than caffeine, 
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only 1:1 co-crystal could be thermodynamically obtained. In ethyl acetate with reduced relative 
solubility between the components, the 2:1 zone became accessible and reproducible 
crystallization conditions were identified. Croker et al. synthesized a new 1:1 co-crystal of p-
toluene sulfonamide (TSA) and triphenylphosphine oxide which had structural similarity to the 
previously reported 3:2 co-crystal.60 The ternary phase diagrams for this co-crystal system were 
constructed in acetonitrile and dichloromethane. Solvent dependent congruent and incongruent 
dissolution was depicted. For the congruent case of 1:1 co-crystal in acetonitrile, isolation of 
the co-crystal from solution was possible by solvent evaporative technique regardless of the 
point at which evaporation was stopped. In dichloromethane with incongruent dissolution, 
evaporation could result in either TSA, 3:2 co-crystal or 1:1 co-crystal depending on the extent 
of solvent evaporation. Zhang and coworkers studied the thermodynamics and crystallization 
of 1:1 co-crystals of theophylline with salicylic acid, glutaric acid, and oxalic acid.85 They 
investigated the effect of polymorphism in pure components on the theophylline-glutaric acid 
co-crystal phase diagram and estimated the thermodynamic parameters associated with co-
crystal formation. The Gibbs energy of co-crystal formation from its solid components, 
calculated from solubility data was negative indicating co-crystal stability. Croker and 
Rasmuson proposed isothermal slurry conversion using ternary phase diagrams for co-crystal 
manufacture.86 Necessary starting composition was identified for both 1:1 and 3:2 
stoichiometry to obtain pure product. They demonstrated the efficiency of this process in terms 
of both purity and productivity. Another method for the production of co-crystals based on 
phase diagrams is reported in literature wherein carbamazepine-saccharin was selected as a 
model.87 The co-crystallization method relying on mixing two solutions of eutectic composition 
based on the phase diagram was proposed. The idea was that the overall composition would lie 
on the straight line joining the two eutectic solutions and accordingly be in the co-crystal region. 
Bachhi et al. constructed ternary phase diagrams for a liquid API, propofol with solid 
coformers, bipyridine, and phenazine. Co-crystallization proved to stabilize the liquid drug in 
crystalline form. Seaton and co-workers investigated the effect of solvent on the selective 
growth of a molecular complex using benzoic acid-isonicotinamide co-crystal which existed in 
1:1 and 2:1 forms.88 Boyd and co-workers investigated the solubility and crystal growth of 1:1 
co-crystal formed between benzoic acid and isonicotinamide in 95% ethanol.89 From the 
solubility data of the pure components and mixed phases, Gibbs energy of co-crystal formation 
from its pure components was determined to be around -10.8 kJ/mol. In another contribution, 
Sun et al. showed the effect of solvent and temperature on phase diagrams indomethacin-
nicotinamide co-crystal, where indomethacin formed solvate with methanol. A temperature 
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increase and using mixed solvents suppressed the solvate formation and hence caused the 
thermodynamic solvate region to disappear in the ternary phase diagram.89 90 
Despite extensive research in the field of co-crystals in recent years, large-scale production 
remains a matter of concern for the pharmaceutical industry. This is because of insufficient 
understanding of the co-crystal stability and lack of a robust manufacturing technology. There 
are studies in the literature that have proposed strategies for co-crystal manufacture, however, 
their feasibility and efficacy at large scales are not understood. Hence, more work is needed to 
fill these gaps in the present literature. 
2.3 Solvate 
‘Solvate’ can be defined as a crystalline phase in which solvent molecule is incorporated into 
the crystal lattice of the API. When the solvent is water, the resultant structures are termed 
‘hydrates’. The possibility of hydrate formation is higher than that of solvates because of 
atmospheric humidity and small size and presence of both hydrogen bond acceptor and donor 
functionality in the molecules.91 
Two scenarios may cause solvate formation. The first being an imbalance between the number 
of hydrogen bond acceptors and donors in a structure, meaning the potential intermolecular 
interactions are not fully satisfied. In such case, solvent molecule stabilizes the structure by 
providing strong intermolecular interactions and improving the packing efficiency. The second 
being, solvent inclusion acts as space filler and reduces the void space.92-94 Other ways in which 




Figure 2.5. A schematic showing different ways in which a solvent can associate with a solid.95 
2.3.1 Importance 
Generally, low molecular weight API molecules have a tendency to form solvates and hydrates 
due to their small size.91 However, they are stable only in contact with the solvent. Desolvation 
occurs sooner or later if they are exposed to ambient conditions. This can provide new routes 
to access other novel forms of the API like polymorphs, which might be inaccessible by the 
conventional crystallization technique.95 During processing, storing or manufacturing APIs, 
exposure to solvent can lead to the formation of solvates. Some solvates have known to improve 
the physicochemical properties of the API95, 96 This makes the study and characterization of 
solvates important as they can not only improve the physicochemical properties but also affect 
the manufacturing processes.  
Many sulfonamide drugs exhibit polymorphism30, 97 and possess the ability to form 
solvates.98, 99 Incidentally, over a hundred solvates of sulfathiazole are known to exist.98 
Seven solvates each sulfamethazine and sulfamerazine have been reported in the 
literature.100 The crystal structures of solvates of SMT with methanol, pyridine and 3-




Solvent mediated transformation or slurry method is one of the most common technique to 
prepare powder solvates. In this method, excess API is charged to the solvent and allowed to 
equilibrate for a certain amount of time. This can lead to the formation of solvates. Cooling 
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Chapter 3: Materials, methods and techniques 
3.1 Introduction 
This chapter gives a description of the materials and chemicals used, and the instrumentation 
involved.  
3.2 Materials 
The model API involved in this study is sulfamethazine (SMT). A part of this study also 
includes the API, sulfamerazine (SMR). The coformers studied are salicylic acid (SA), 3-
methylsalicylic acid (3mSA), salicylamide (SAL), benzamide (BEN), aspirin (ASP), anthranilic 
acid (AA), and nicotinamide (NIC). The solvents used in this study are acetonitrile, methanol, 
dimethylsulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA) 
and water. 
SMT (CAS Registry Number 57-68-1), purity >99%; SMR (CAS Registry Number 127-79-7), 
purity >99%; SA (CAS Registry Number 69-72-7), 3mSA (CAS Registry Number 83-40-9), 
purity >97 %; ASP (CAS Registry Number 50-78-2), purity >99 %, methanol (CAS Registry 
Number 67-56-1, HPLC grade, purity >99.9 %) were purchased from Sigma Aldrich. BEN 
(CAS Registry Number 55-21-0), purity >98.5 % and AA (CAS Registry Number 118-92-3), 
purity >98 %; DMSO (CAS Registry Number 67-68-5), purity >99.8 %; DMA (CAS Registry 
Number 127-19-5, purity >99.9 %) were purchased from Acros Organics. Acetonitrile (CAS 
Registry Number 75-05-8, HPLC grade, purity >99. 9%) and DMF (CAS Registry Number: 
68-12-2, purity >99.8 %) were purchased from Fisher Chemicals. NIC (CAS Registry Number 
98-92-0), purity 99% was purchased from Alfa Aesar. All the chemicals were used as received. 








Table 3.1. Chemical structures and properties/uses of APIs and coformers used in this 
study. 







Uses: Antibacterial and 
anti-infective, used to 
treat vaginal infections 
Properties: 
SMT: Monomorphic 
Tm, onset= 198.38 
oC 
∆fusH (Tm) = 36.2 kJ/mol 
SMR: 3 polymorphs 
Tm, onset = 239.13 
oC 













Uses: Active as Vitamin 
L1, necessary for 
lactation, used for 
production of saccharine 
and loop diuretics 
Properties: 3 polymorphs  
Tm, onset = 144.56 
oC 




Uses: Analgesic, used for 
production of aspirin 
Properties: Monomorphic 
Tm, onset = 158.20 
oC 




Uses: Form of Vitamin 
B3, used to treat pellagra 
Properties: 4 polymorphs 
Tm, onset = 158.20 
oC 






Uses: Analgesic and anti-
pyretic 
Properties: 2 polymorphs 
Tm, onset = 158.20 
oC 





benzamides used as 
neuroleptics 
Properties: 3 polymorphs 
Tm, onset= 125.10 
oC 








Properties: 3 polymorphs  
Tm, onset=  139.05 
oC 






Uses: Fibrinolytic activity 
in human plasma 
Properties: Monomorphic  
Tm, onset= 163.15 
oC 
∆fusH (Tm) = 25.7 kJ/mol 
 
3.3 Equipment 
3.3.1 Powder X-ray Diffraction (PXRD) 
PXRD data were collected in reflectance mode using either PANalytical Empyrean 
diffractometer or X’Pert MPD PRO diffractometer using Cu radiation source (γ = 1.541 Å) 
operating at 40 kV and 40 mA at room temperature. Samples were scanned between 2θ values 
of 5 and 40°. With Empyrean, the parameters step size and time were 0.01313° 2θ/s, 73 s per 
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step and with X’Pert the respective parameters were 0.0167o 2θ/s and 24.76 sec/step 
respectively.  
3.3.2 Single Crystal X-ray diffraction 
Single-crystal X-ray diffraction measurements were collected on a Bruker Quest D8 Mo Sealed 
Tube (γ = 0.71073 Å), equipped with CMOS photon detector. Data were integrated with 
BRUKER APEX 3 and corrected for absorption using empirical methods (SADABS or 
TWINABS) based upon symmetry-equivalent reflections combined with measurements at 
different azimuthal angles. The structures were solved with the SHELX structure solution 
program using Direct Methods and refined with the olex2 refinement package using Gauss-
Newton minimisation or against Fobbs with X-Seed. Non-hydrogen atoms were refined 
anisotropically and hydrogen atoms were placed in calculated positions refined using idealized 
geometries (riding model) and assigned fixed isotropic displacement parameters. 
This was performed by Pauric Bannigan, Peraka Krishna Sumanth and Matteo Lusi. 
3.3.3 Thermogravimetric Analysis (TGA) 
TGA experiments were carried out under nitrogen using TGA instrument TA Q50 V20.13 Build 
39. Samples were placed on platinum pans and heated up to 500 °C at a ramp rate of 20 °C min-
1. 
3.3.4 Differential Scanning Calorimetry (DSC) 
Two types of DSC equipment were used:  
1. DSC was performed on a Perkin Elmer Pyris 1 DSC instrument under a nitrogen 
environment at a heating rate of 10 °C min−1. Hermetic aluminium pans were used to 
hold 2-4 mg of the samples crystals and sealed using a crimping press. The instrument 
was calibrated using samples of indium and lead. This was used to characterize the three 
new solvates of SMT and new co-crystals obtained by microwave-assisted slurry 
conversion. 
2. A TA Instruments Q2000 differential scanning calorimeter, at a constant heating rate of 
3 K∙min-1 was used to determine the melting temperatures and associated enthalpies of 
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fusion of SMT-SA and SMT-3mSA co-crystals. Heat capacities of the solid states and 
melts were determined using the same instrument in temperature-modulation mode. A 
modulation period of 100 s, an amplitude of 1 K and a constant underlying heating rate 
of 5 K min-1 were used. Heat capacity data for the solid forms were collected in an initial 
heating step, and data for the supercooled melts in a second heating step following rapid 
cooling to a point below the melting temperature but above the typical recrystallization 
temperature. In these experiments, evenly distributed powder samples of approx. 5 mg 
were encapsulated in Tzero aluminium pans, the furnace was purged with nitrogen gas 
at 50 mL·min-1, and the instrument was calibrated against the melting properties of 
indium. The heat capacity signal was calibrated using a linear function of temperature 
against a sapphire sample. This was performed by Michael Svärd. 
3.3.5 High-Performance Liquid Chromatography (HPLC) 
HPLC analysis was performed on an “Agilent Technologies 1260 Infinity Series” comprising 
of a solvent 1260 Quat delivery pump, auto-injector, absorbance UV spectrophotometric 
detector (275 nm) and Agilent ChemStation software. A Macharey-Nagel EC Nucleodur C18 
column (4.6 × 100 mm) was used. 
The mobile phase used for separating SMT and SA, and SMT and 3mSA was methanol/2 % 
acetic acid in water (88/12, v/v); for SMT and NIC, SMR and SAL, and SMR and AA was 
methanol/ 2 % acetic acid in water (50/50, v/v). The two components were well separated. 
(A/B; a/b, v/v means a volume parts of solvent ‘A’ and b volume parts of solvent ‘B’) 
3.3.6 Raman and FT-IR spectroscopy 
Two types of Raman equipment were used:  
1. Micro-Raman measurements were performed on an InVIA Reflex spectrometer 
(Renishaw) coupled to an optical microscope (DM2500, Leica). Instrument calibration 
was performed using the Si (100) peak (520.5 ± 1 cm−1) (50× objective, laser power 10 
mW, acquisition time 10 s, 1 accumulation). The 785 nm excitation laser was used 
throughout. The as-received SMT was packed into a 5 mm diameter hole in a steel slide 
and the powder was lightly compacted with a glass slide to produce a relatively flat 
sample surface. Crystals of the solvates were dispersed on glass slides. Spectra were 
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collected by point mapping (20× objective, laser power 1 or 5 mW, acquisition time 10 
s, 1–5 accumulations, n ≥ 10) over the spectral range of interest. Spectra collection and 
processing were performed with the WIRE™ 4.1 software (Renishaw). This was done 
for solvates, performed by Clare Crowley. 
2. Raman Spectroscopy was carried out on solid samples using Kaiser Raman Rxn2™ 
Multi-channel Raman Analyzer with laser wavelength 785 nm and spectral range from 
150-3425 cm-1. This was performed for the new co-crystals synthesized by microwave 
assisted slurry conversion, by Kiran Ramisetty. 
 
Infrared (FT-IR) spectra were collected on PerkinElmer, model Spectrum 100 with Universal 
ATR FT-IR between 4000-400 cm-1, using 3 scans and a resolution of 4 cm-1. 
3.3.7 Variable Temperature Powder X-ray Diffraction (VT-PXRD) 
VT-PXRD was used to study the characteristic of solvates. It was performed on a PANalytical 
X'pert MPD Pro in reflectance mode with CuKα1,2 radiation (γ = 1.541 Å) operating at 40 kV 
and 40 mA and equipped with an Anton-Paar TK 450 hot stage. Samples were scanned between 
2θ values 5 and 40° with a scan step size of 0.01313° 2θ/s and 73 s per step under nitrogen 
atmosphere. Scans were carried out for each solvate at 25 °C, at desolvation temperatures, at 
10 °C above and below the desolvation temperature up to 200 °C (which was the highest 
possible scan prior to melting of the samples). 
3.3.8 Optical Microscopy 
An inverted light optical microscope (Olympus IX53) integrated with Olympus SC100 camera 
combined with a PC with image/video capture using Olympus Stream Essentials software was 
used to capture micrographs for the solvate and co-crystal single crystals manufactured by the 




Chapter 4. Investigation of solid-liquid phase 




This study discusses the influence of solvent and temperature on the solid-liquid phase diagrams 
of co-crystals by using 1:1 SMT-SA co-crystal as the model system. For this, the ternary phase 
diagrams of this co-crystal have been constructed in three solvents and at three temperatures. 
The choice of solvents has a dramatic effect on the appearance of the phase diagram and on the 
co-crystal dissolution behavior. The impact of temperature on the 20 oC range is found to be 
weak. The coformer to API solubility ratio does not provide an absolute method to determine 
co-crystal dissolution behavior. The stability of this co-crystal has been investigated by 
thermodynamic parameters like Gibbs energy, enthalpy and entropy change. The slurry 
conversion co-crystallization is shown to be an effective technique for pure co-crystal synthesis 
in any of the solvents, starting compositions guided by the ternary phase diagrams. Co-crystal 
yield and volumetric productivity have been determined to provide examples for the efficiency 
of the slurry conversion crystallization. A relationship between the size of the region in the 
ternary phase diagram where co-crystal is the stable phase and the solubility ratio of the co-





4.1.1 Solvent selection 
Solvents were selected with the ambition to cover congruent as well as incongruent conditions, 
with the starting point in the expectation that a symmetric and congruent system would be 
obtained when the pure components had similar solubility, and asymmetric and incongruent 
systems obtained for larger solubility differences. Preliminary solubility experiments were 
carried out, based on which the three solvent systems were selected. The solvents evaluated 
were methanol, acetonitrile, water, chloroform, acetone, ethyl acetate, dimethyl sulfoxide, N, 
N-dimethyl acetamide, N, N-dimethyl formamide, and dimethyl sulfoxide-methanol mixtures 
of different ratios. The preliminary solubility experiments revealed a high SA to SMT solubility 
ratio in ethyl acetate and in methanol. Methanol was chosen as an example of a likely 
incongruent dissolution over ethyl acetate, based on a higher SMT solubility. In acetonitrile, 
the solubility ratio was lower than in acetone, and was selected as a likely congruent dissolution 
system. In chloroform, the settling velocity of solid was low because of similar densities of 
SMT, SA and chloroform, and in water, the problem was the same. Hence, for practical reasons, 
water and chloroform were not selected. SMT exhibits about the same low solubility in all 
solvents tested except for DMSO, DMA and DMF. However, SMT forms solvates in pure 
DMSO, DMF and DMA. A few DMSO-methanol mixtures were evaluated with the intent to 
keep the DMSO content high. A 7:3 (v/v) DMSO-methanol mixture, prepared by mixing 7 
volume parts of DMSO and 3 volume parts of methanol, was chosen as it fulfils the three targets, 
i.e. high SMT solubility, no solvate formation and a low solubility ratio. 
4.1.2 Measurement of solubility 
Solubility of the pure compounds (SMT and SA) was determined gravimetrically in methanol 
and acetonitrile at desired temperature (10, 20 and 30 oC). HPLC was employed to determine 
SMT and SA solubility in 7:3 (v/v) dimethyl sulfoxide–methanol mixture at 20, 30 and 40 °C. 
The first step to both the techniques involved preparing saturated solutions, for each of which 
an amount of solid solute in excess of the solubility was added to ∼5 mL of the solvent at the 
desired temperature. The solutions were equilibrated for a period of 24 hours under continuous 
agitation. The agitation was then stopped, and the solids allowed to settle for a period of 10 
minutes (methanol, acetonitrile), or 60 minutes (DMSO–methanol) due to slow settling. 
Samples of the saturated supernatant clear liquid were pipetted out using a syringe. 
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For gravimetric determination, approx. 1 mL of the solution was filtered into a pre-weighed 
glass vial (m1) using a 0.2 μm PTFE syringe filter. The vial was weighed immediately and the 
mass recorded as m2. The solvent was then allowed to evaporate by placing the vial for a 
sufficient time (usually overnight) in a fume hood until dry and the mass recorded till there was 
no further loss. The dried vial was then moved to a vacuum oven at 50 °C for 1 hour, after 
which no further decrease in weight could be recorded. The mass of the vial containing dry 
solids (m3) was recorded. The syringes, vials and the filters were pre-heated before sampling 
solutions at high temperatures. The solubility was calculated as (m3 − m1)/(m2 − m3). The PXRD 
of a sample of the solid material present in the equilibrium slurry (after filtration) was recorded 
to confirm the identity of the solid form. 
Because of the high boiling points and accordingly low volatilities of DMSO, DMA and DMF, 
the gravimetric method was not feasible for DMSO-methanol solutions. Solution 
concentrations were determined by HPLC for the determination of the solubility of SMT and 
SA in this solvent system. Solubility determination entailed the construction of calibration 
curves i.e. peak area vs. concentration using stock solutions of known concentrations of solutes. 
The calibration lines for all cases showed good linearity (R2 = 0.99). The saturated solution 
samples were filtered into clean glass vials. The samples were diluted and the peak areas were 
obtained. The dilution factor was accounted for, to obtain the corresponding concentrations 
using the calibration curves. 
4.1.3 Determination of ternary phase diagram 
Invariant points represent solution concentrations at which two solid phases (API + co-crystal 
or coformer + co-crystal) are at equilibrium with the same solution. These points were 
determined by equilibrating different mixtures of the two solid co-crystal components with the 
solvent and then analysing both the solid and the solution phase. At constant temperature, API 
and coformer were mixed with the solvent and magnetically stirred for sufficient time to reach 
equilibrium. Following this, the solid material and the saturated solution were separated by 
filtration. An aliquot of the saturated solution was diluted with pure solvent and analysed by 
HPLC. The concentration of SMT and SA, respectively, was determined from the calibration 
curves in the pure solvent. Using another aliquot of the saturated solution, gravimetric analysis 
was employed to determine the total solute and solvent content in the liquid phase. The solid 
material was analysed by PXRD and DSC. The solubility of the pure components and the 
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concentrations corresponding to the invariant points were plotted in a ternary diagram using the 
Prosim Ternary Diagram software.1 
4.1.4 Process experiments 
Isothermal slurry conversion experiments2-4 were carried out for investigation of the 
manufacturing of the SMT-SA co-crystal. Guided by the determined ternary phase diagram in 
each solvent at 30oC, two points were selected inside the region where the co-crystal only is 
thermodynamically stable. The two points were selected to compare a high and a low solid 
loading (refer to Table 4.3 for mass fractions). Pure solid components and the solvent were 
mixed in proportions corresponding to each point, and the mixture was stirred for 24 hours. The 
solids were then separated from the solution by filtration and allowed to dry. The mass of the 
dry solids was recorded (product mass) and was confirmed by PXRD to be pure co-crystals. 
The co-crystal yield was calculated as the mass of obtained co-crystals divided by the total mass 
of API and coformer used, and the volumetric productivity was calculated as the mass of 
obtained co-crystals divided by the total slurry volume (API, coformer and solvent). 
4.2 Results 
4.2.1 Solid phase characterization 
Pure SMT and SA, as well as the 1:1 co-crystal, each has only one reported crystalline form. In 
the present work, the structures with the CSD refcodes SLFNMD10, SALIAC19 and GEYSAE 
have been used. The PXRD pattern obtained for the 1:1 co-crystal matches with the simulated 
pattern obtained from the structure GEYSAE (Figure 4.1a) confirming the purity of the co-
crystal. The co-crystal features strong hydrogen bonding interactions between the hydroxyl and 
carbonyl functionalities of SA with the pyrimidine ring nitrogen and the sulfonamide N-H 




Figure 4.1. Experimental and calculated PXRD patterns for SMT-SA co-crystal (a), the main 
hydrogen-bond motif in the crystal structure of the 1:1 SMT-SA co-crystal (b).5 
4.2.2 Solubility, ternary phase diagram, effect of solvent and temperature 
The solubility of SMT and SA in the three solvents at three temperatures are given in Table 4.1, 
as averages of n=4 experiments, together with standard deviations. The solubility values of both 
coformers in methanol and acetonitrile agree well with those reported in the literature.6, 7 The 
temperature dependence of the solubility of pure SMT and SA in 7:3 (v/v) DMSO-methanol 
mixture is shown in Figure 4.2 as van’t Hoff plots. In all solvents, the solubility of SA is higher 
than that of SMT, by approx. a factor 60 in methanol, 12 in acetonitrile and 3 in the DMSO-
methanol mixture, at 30oC. 
Figure 4.2. Van’t Hoff plots for SMT and SA in 7:3 (v/v) DMSO-methanol mixture, where 




Table 4.1. Solubility of SMT and SA in methanol, acetonitrile and 7:3 (v/v) DMSO-methanol 














(M/M) SMT SA SMT SA SMT SA 
Methanol 
10 0.0092 0.4788 0.0262 2.7456 0.0010 0.0014 104.7 
20 0.0140 0.5688 0.0399 3.2615 0.0011 0.0015 81.7 
30 0.0228 0.7007 0.0650 4.0178 0.0013 0.0018 61.8 
Acetonitrile 
10 0.0102 0.0634 0.0291 0.3742 0.0014 0.0019 12.8 
20 0.0151 0.0881 0.0431 0.5051 0.0018 0.0016 11.7 




20 0.4762 0.7011 1.7237 5.1152 0.0084 0.0079 2.96 
30 0.5029 0.7345 1.8202 5.3727 0.0074 0.0081 2.95 
40 0.5232 0.7620 1.8940 5.5602 0.0078 0.0071 2.93 
 
 
In methanol, the phase diagram (Figure 4.3a) is rather asymmetric as would be expected given 
the high solubility ratio of SA to SMT (Table 4.1), and the co-crystal region is significantly 
skewed towards the more soluble component, SA. In addition, the region where the co-crystal 
is the stable solid phase is very narrow. A very narrow co-crystal region makes the 
manufacturing process more difficult to design and operate. The dissolution of the co-crystal is 
incongruent, i.e. it is not possible to establish a solid-liquid equilibrium between the co-crystal 
solid phase and a stochiometric solution. For this reason, the solubility of the co-crystal cannot 
be determined by traditional methods. Continued dissolution of this co-crystal would tend to 
move the solution composition to the point where the stable solid phase is a mixture of SMT 
and co-crystal, i.e. the invariant point. The phase diagram at three temperatures as a function of 






Figure 4.3. Zoom-in view of the ternary phase diagram of SMT-SA co-crystal system in 
methanol at 30 oC. Values are in mass fractions. The blue dotted line is the 1:1 stoichiometric 
line. Regions in the diagram are as follows: (1) solution phase; all other regions consist of a 
saturated solution in contact with (2) SMT, (3) SMT + co-crystal (red filled circle), (4) co-





square and triangle represent the experimental data. The points M1 and M2 (filled black 
diamonds) represent starting compositions for co-crystal yield and volumetric productivity 
determination. (a), Phase diagrams at 10 (red), 20 (light blue) and 30oC (green) in methanol. 
The horizontal lines are the solubilities of pure SMT at 10, 20, 30oC in methanol. The points 
(filled circles) depict the invariant points at the three temperatures (b). 
In acetonitrile, the solubility of SMT is slightly higher while that of SA is lower, leading to a 
reduced solubility ratio between the two components (Table 4.1). The phase diagram is quite 
symmetric and the co-crystal dissolves congruently. Since the solubility of SA is still 
approximately 12 times higher than that of SMT, the co-crystal region is slightly skewed 
towards the SA side of the diagram, i.e. towards the more soluble component (Figure 4.4a). The 
co-crystal region is clearly broader than in methanol. Since the co-crystal dissolves congruently, 
the solubility of the co-crystal can be gravimetrically determined (Table 4.2). The van’t Hoff 
plot of the solubility data for the co-crystal is shown in Figure 4.5, from the slope (-∆H/R) of 
which the van’t Hoff enthalpy of solution is determined to be +22.2 kJ/mol (1:1 complex). The 
corresponding values for the pure components SMT and SA in acetonitrile are +25.4 and +20.8 






Figure 4.4. Zoom-in view of the ternary phase diagram of SMT-SA co-crystal system in 
acetonitrile at 30oC.Values are in mass fractions. The blue dotted line is the 1:1 stoichiometric 
line. Regions and various points in the diagram are as same as marked in Figure 4.3. The points 






volumetric productivity determination (a), Phase diagrams at 10 (red), 20 (light blue) and 30oC 
(green) in acetonitrile. The horizontal lines are the solubilities of SMT at 10, 20, 30oC in 
acetonitrile. The points (filled circles) depict the invariant points at the three temperatures (b). 
 
Figure 4.5. The experimental solubility of pure SMT and the co-crystal in acetonitrile (a), Van’t 
Hoff plot of the co-crystal in acetonitrile (b). 
The co-crystal intrinsic solubility (SAB) can be estimated from Equation 2.10 at 10, 20 and 30 
oC in acetonitrile (congruent case) using concentrations obtained from HPLC well matching 
those determined by the gravimetric method (Table 4.2). The Gibbs energy of formation of the 
co-crystal from its pure solid components (Equation 2.11) can be determined by Equation 2.16,8 
by approximating the activities with the concentrations in mol/L. Using the co-crystal solubility 
data in acetonitrile (a congruent system), the Gibbs energy of co-crystal formation at 10, 20 and 
30oC is estimated to be -5.7, -7.1 and -7.7 kJ/mol, respectively. The Gibbs energy of formation 
has also been estimated using the average Ksp (Equation 2.16) in the three solvent systems; the 
data is reported in Table 4.2. The values are all quite close to the values obtained from the co-
crystal solubility data. Altogether, the negative value of the Gibbs energy change reveals that 
the formation of the 1:1 co-crystal from pure solid SMT and SA is a spontaneous process, and 
that the co-crystal is thermodynamically stable compared to a physical mixture of pure SMT 
and SA solid phases. With increasing temperature, the free energy change becomes more 
negative, signifying increased stability of the co-crystal. 
The entropic (Equation 2.18) and enthalpic (Equation 2.19) components of the Gibbs energy of 
formation can be determined. The calculated Gibbs energies are plotted in the appropriate 
coordinates in Figure 4.6, from which estimates of the entropy and the enthalpy of formation 
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are determined from the slopes. The entropy of co-crystal formation is found to be 0.1015 
kJ/(K·mol), i.e. the co-crystal formation is associated with a positive entropy change. The 
estimated co-crystal enthalpy of formation is +23.1 kJ/mol, which agrees closely with the 
average value of +22.8 kJ/mol obtained using Eq. 2.17. Hence, the SMT-SA co-crystal 
formation from its solid components is shown to be an endothermic processes, i.e. energy needs 
to be provided to synthesize the co-crystal. Obviously, the conclusion is that the formation of 
the co-crystal is entirely driven by a favorable entropy increase. 
 
Figure 4.6. A plot of ∆G vs. T to find the entropy of SMT-SA co-crystal formation (a), Gibbs-
Helmholtz plot to determine the enthalpy of SMT-SA co-crystal formation (b). 
The 7:3 (v/v) mixture of DMSO and methanol was chosen to reach a higher solubility of SMT. 
The solubility ratio between the two co-crystal components in this solvent is very low (~ 2.9), 
and hence this system is expected to be congruent. However, as shown in Figure 4.7a, the 
system is in fact shown to be incongruent, even though the co-crystal region is very broad and 
only slightly skewed away from the 1:1 stoichiometric line (Figure 4.7a). The effect of 
temperature on the phase diagram is shown in Figure 4.7b. 
In accordance with the SA to SMT solubility ratio, the co-crystal shows incongruent dissolution 
in methanol where the ratio is high and congruent dissolution in acetonitrile where the ratio is 
low. However, for an even lower solubility ratio in 7:3 (v/v) DMSO-methanol the co-crystal 
unexpectedly shows incongruent behavior. The nature of co-crystal dissolution was confirmed 
by separate co-crystal dissolution experiments. In methanol and DMSO-methanol, the 
originally pure co-crystal solid-phase transformed into a mixture of solid SMT and co-crystal, 
whereas in acetonitrile, a pure co-crystal solid was maintained. So, even if the co-crystal 
dissolves nearly congruent in 7:3 (v/v) DMSO-methanol it is perfectly clear that the system is 
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incongruent. In addition, the co-crystal region for this system does not change systematically 
towards the SMT axis compared to the acetonitrile system as would have been expected from 
the difference in the solubility ratio. Accordingly, it can be concluded that the co-former to API 
solubility ratio for the SA-SMT system cannot be safely used as a guide to the nature of the co-
crystal dissolution behavior. However, quite clearly the solvent has a major influence on the 
nature of co-crystal dissolution and the overall appearance of the phase diagram. 
With increasing temperature the solubility of all the solid phases increase, which leads to a shift 
of the various solid-state regions down towards the solid SMT-SA axis in the ternary phase 
diagram. This leads to a larger region for the solution phase region. Temperature changes did 






Figure 4.7. Full-scale ternary phase diagram of SMT-SA co-crystal system in 7:3 (v/v) DMSO-
methanol mixture at 30oC.Values are in mass fractions. The blue dotted line is the 1:1 
stoichiometric line. Regions and various points in the diagram areas are same as marked in 
Figure 4.3. The points D1 and D2 (black filled diamonds) represent starting compositions for 
co-crystal yield and volumetric productivity determination (a), Phase diagrams at 10 (red), 20 
(light blue) and 30oC (green) in 7:3 (v/v) DMSO-methanol. The horizontal lines are the 
solubilities of SMT at 10, 20, 30oC in 7:3 DMSO-methanol. The points (filled circles) depict 
the invariant points at the three temperatures (b). 
The experimentally determined invariant points for the three solvents in terms of mole fractions 
are given in Table 4.2, together with the corresponding Ksp values obtained from Equation 2.9. 
Obviously, the value depends on the solvent. The order in which Ksp varies is DMSO-methanol 
> methanol > acetonitrile. In each solvent, the Ksp value and the corresponding co-crystal 
solubility increase with temperature. In methanol and acetonitrile, there is just a small 
difference in the Ksp values obtained from the two invariant points. However, in the DMSO-
methanol mixture, the Ksp difference is much higher, most likely because at higher 
concentrations the error associated with neglecting the activity coefficients becomes larger. For 
the congruent acetonitrile case, the Ksp for the co-crystal is between the Ksp values obtained from 
the two invariant points.  
The width of the region where the co-crystal is the most stable phase can be measured as the 
linear distance between the two invariant points as per Equation 4.1. A schematic representing 




Equation 4.1  𝑑 = √(𝑥1 − 𝑥2)2 + (𝑦1 − 𝑦2)2 + (𝑧1 − 𝑧2)2 
Based on this, the width of the co-crystal region decreases in the order DMSO-methanol > 
acetonitrile > methanol, and is inversely proportional to the solubility ratio between the two co-
crystal components (SA/SMT, Table 4.1) i.e. the smaller the solubility ratio, the wider the co-
crystal region (Figure 4.9). 
 
Figure 4.8. A schematic representing the width of the region where co-crystal is the stable 
solid phase (d).  
 
Figure 4.9. A plot showing the relationship between the reciprocal of the solubility ratio of 
SA/SMT vs. the width of the region in of ternary phase diagram where co-crystal is the most 









Solid phases at 
equilibrium 















SMT + co-crystal 0.0015 0.0056 0.9929 5.8x10-3   
-6.0 
SA + co-crystal 0.0014 0.0066 0.9920 5.4x10-3   
20 
SMT + co-crystal 0.0020 0.0072 0.9908 8.9x10-3   
-6.5 
SA + co-crystal 0.0018 0.0080 0.9902 8.2x10-3   
30 
SMT + co-crystal 0.0030 0.0092 0.9878 1.7x10-2   
-6.8 










SMT + co-crystal 0.0022 0.0010 0.9968 7.9x10-4   
-5.9 SA + co-crystal 0.0004 0.0059 0.9936 1.0x10-3   
Co-crystal 0.0015 0.0015 0.9969 8.6x10-4 0.0293 0.0304 
20 
SMT + co-crystal 0.0025 0.0012 0.9963 1.1x10-3   
-6.9 SA + co-crystal 0.0006 0.0064 0.9929 1.7x10-3   
Co-crystal 0.0017 0.0017 0.9966 1.5x10-3 0.0388 0.0404 
30 
SMT + co-crystal 0.0033 0.0015 0.9952 1.8x10-3   
-7.2 SA + co-crystal 0.0010 0.0075 0.9914 3.0x10-3   


















SMT + co-crystal 0.0678 0.0708 0.8613 1.59   
-6.8 
SA + co-crystal 0.0031 0.1949 0.8019 0.23   
30 
SMT + co-crystal 0.0696 0.0738 0.8566 1.71   
-6.3 
SA + co-crystal 0.0042 0.2035 0.7923 0.33   
40 
SMT + co-crystal 0.0721 0.0758 0.8521 1.84   
-6.2 
SA + co-crystal 0.0051 0.2143 0.7806 0.44   




Table 4.3. Mass of SMT, SA and solvent input for isothermal slurry conversion, co-crystal 
mass obtained, and the corresponding co-crystal yield and volumetric productivity. 
Point 





productivity (g/mL) SMT SA Solvent 
M1 0.0700 0.0600 0.8700 0.1423 0.55 0.06 
M2 0.1530 0.0980 0.7490 0.4574 0.91 0.21 
A1 0.0620 0.0380 0.9000 0.1460 0.73 0.06 
A2 0.1968 0.1032 0.7000 0.5819 0.96 0.26 
D1 0.2100 0.2430 0.5470 0.0910 0.10 0.05 
D2 0.3540 0.2780 0.3680 0.4857 0.38 0.29 
*M (methanol), A (acetonitrile), D (DMSO-methanol) 
 
The co-crystal yield and productivity results are given in Table 4.3. The starting overall 
compositions of pure solid SMT, SA and solvent in the experiments are marked in Figure 4.3, 
4.4, and 4.7 by (M1, M2), (A1, A2) and (D1, D2), respectively. The farther away from the solid-
liquid equilibrium line this initial overall composition point is placed, the greater is the surplus 
of material that can transform into solid co-crystal, and hence the higher the potential co-crystal 
yield and productivity. The difference in yield for the different solvents primarily depends on 
the co-crystal solubility. A high solubility leaves a greater amount dissolved in the solution at 
the end of the process. The yield can be improved by adding more pure solid components at a 
stoichiometric ratio. The very narrow co-crystal region in methanol requires high precision in 
dosing the components. In spite of a large co-crystal region in DMSO-methanol, a limiting 
factor for DMSO-methanol is the high boiling point, which makes it difficult to completely 
remove the toxic solvent from the crystals after filtration. Irrespective of the system being 
congruent or incongruent, the pure co-crystal can be synthesized by slurry co-crystallization as 
long as the liquid composition starting point is along the curve where the co-crystal is in 
equilibrium with the solution and stoichiometric amounts of solid are further added. It may be 
noted that it is favorable from a yield point of view if the phase diagram is skewed towards the 




Ternary phase diagrams have been constructed for sulfamethazine and salicylic acid in three 
solvents: methanol, acetonitrile and a dimethyl sulfoxide-methanol 7:3 mixture, at three 
temperatures. The shape of the phase diagram depends strongly on the solvent. The choice of 
solvent can make the co-crystal system congruent or incongruent, and can significantly affect 
the width of the co-crystal region. The co-crystal dissolves incongruently in methanol and (7:3 
v/v) DMSO-methanol mixture, whereas it shows congruent dissolution in acetonitrile. The 
impact of temperature on the phase diagram is weak over the 20oC range investigated. The 
solubility ratio of the two co-crystal components does not afford a simple reliable method to 
predict whether the co-crystal system becomes congruent or incongruent. The Gibbs energy of 
the SMT-SA co-crystal formation from its solid pure components is estimated to be -5.7, -7.1, 
and -7.7 kJ/mol at 10, 20 and 30oC, revealing that the co-crystal is thermodynamically stable in 
relation to the pure components. In all three solvents, a slurry conversion process can provide 
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This chapter aims to discuss the three new solvates of sulfamethazine (SMT) that 
formed during the process of solvent selection for SMT-SA co-crystal phase diagram 
construction. The three solvates, all in 1:1 stoichiometry, with N,N-dimethylacetamide 
(DMA), N,N-dimethylformamide (DMF) and dimethylsulfoxide (DMSO) were 
characterized by various analytical techniques. The solubility of solvates in their 
respective solvents was determined. Thermal analysis was employed to investigate the 
thermal stability and desolvation temperatures of the solvents from the solvate crystal 
structure. Desolvation experiments and Variable Temperature-PXRD were performed 





5.1.1 Preparation of solvates 
The solvates were prepared by slurry method wherein an excess amount of anhydrous SMT in 
terms of solubility was charged to the three different solvents (DMF, DMSO and DMA) and 
allowed to equilibrate for at least 24 hours at 30 °C. The slurry was filtered and the solid solvate 
obtained was characterised. For structure elucidation of solvates by single-crystal XRD, single 
crystals of the solvates in their respective solvents were grown by cooling crystallization. This 
required preparing a saturated solution of SMT in each solvent at 30 °C. The saturated solutions 
were filtered into preheated vials, heated at 40 °C for 30 minutes, cooled to 20 °C and left to 
stand at 20 °C until single crystals were obtained. The single crystals were surface dried on a 
Whatman paper and used immediately to be analysed by single-crystal XRD. To prevent 
desolvation, the crystals were preserved in the solvent. 
5.1.2 Determination of solubility 
The solubility of the solvates in their respective solvents was measured by using the HPLC. 
Same procedure as mentioned in Section 4.1.2 was followed.  
5.2 Results 
5.2.1 Crystal Structure Analysis 
The crystallographic data collected for the three novel SMT solvates are summarized in Table 
5.1. The hydrogen bonding parameters of the three solvates are given in Table 5.2.  The 
molecular packing in pure solid SMT along the a crystallographic axis is depicted in Figure 5.1 
showing four SMT molecules held together through two intermolecular hydrogen bonds of the 
order N1-H---N3/N4 (~ 3.2 Å) and N2-H---O1/O2 (~ 2.9 Å), two of each kind.1, 2 The tetrahedral 
nature of the central sulfur atoms leaves bonding angles of ~108° between it, adjacent carbon 
atom of ring 1 as well as O1 and O2. This tetrahedral arrangement sees ring 1 and ring 2 in close 
proximity to each other, steric repulsions between the rings then sees them take up 
conformations where one is at ~103° to the other (measuring the angle between the ring 1-
sulfur-ring 2). In addition, this arrangement maximises the access to the hydrogen bonding sites 
on the drug molecules. In this arrangement, the pyrimidine rings (ring 2) make column-like 
57 
 
structures along the c crystallographic axis, through partial overlaps of the conjugated systems 
in a staggered manner (also called parallel displacement), rings separated by ~3.8 Å (Figure 
5.3). These type of π-π interaction, however, seem to be absent in phenyl rings (ring 1) as a 
phenyl pair (the rings within a pair separated by ~3.3 Å) is separated by the next pair by ~7.1 
Å, exceeding the maximum distance possible for π-π interactions (Figure 5.3). 
 
Figure 5.1. Unit cell of SMT crystal structure, seen down along the ‘a’ crystallographic axis 
showing hydrogen bonds.  
Table 5.1. Crystallographic data for the three novel SMT solvates 
 SMT-DMF SMT-DMA SMT-DMSO 
Stoichiometry 1:1 1:1 1:1 








Formula mass 351.43 365.46 356.47 
Temperature (K) 298(2) 298(2) 298(2) 
Crystal system Monoclinic Orthorhombic Monoclinic 
Space group P 21/n P n a 21 P 21/n 
a (Å) 9.3986(6) 31.336(4) 9.3368(4) 
b (Å) 13.8030(9) 8.0711(10) 13.3286(6) 
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c (Å) 14.5682(10) 15.218(2) 14.8884(6) 
α (o) 90 90 90 
β (o) 71.354(2) 90 107.384(1) 
γ (o) 90 90 90 
V (Å3) 1790.72 (2) 3848.88 (9) 1768.18 (13) 
Z 4 8 4 
calc (gcm-3) 1.304 1.261 1.339 
R-factor (%) 4.68 6.64 4.89 
µ (mm-1) 0.204 0.194 0.320 
θ range  5.444-55.858 5.212-54.972 6.754-55.018 
Index ranges 
-12 ≤ h ≤ 12 
-18 ≤ k ≤ 18 
-19 ≤ l ≤ 19 
-26 ≤ h ≤ 40 
-10 ≤ k ≤ 10 
-19 ≤ l ≤ 17 
-12 ≤ h ≤ 12 
-17 ≤ k ≤ 17 
-14 ≤ l ≤ 19 
Reflections collected 58196 13796 13208 
Independent 
reflections 
4276 [Rint = 0.0242, 
Rsigma = 0.0107]  
7336 [Rint = 0.0509, 
Rsigma = 0.1020] 
3961 [Rint = 0.0136, 
Rsigma = 0.0144 
Final R indexes [I>2σ 
(I)] 
R1 = 0.0467, wR2 = 
0.1334 
R1 = 0.0664, wR2 = 
0.1062 




1.064 1.011 1.079 
Crystal shape Plate* Plate* Plate* 
* refer to Figure 5.2 
 
 
Figure 5.2. Micrographs obtained from optical microscope for solvates of SMT with DMA (a), 
DMSO (b) and DMF (c). 
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Table 5.2. Hydrogen bond interactions in SMT solvates 










N2-H---OC 0.86 2.08 2.78 137.2 
N1-H---O1 0.86 2.83 3.06 97.11 
N2A-H---OB 0.86 2.58 2.70 88.3 
NA-H---O2A 0.86 2.59 3.45 176.8 
DMF 
N2-H---OA 0.86 1.92 2.76 169.4 
N1-H---O1 0.86 2.28 3.04 147.1 
N1-H---OA 0.86 2.43 3.16 142.6 
DMSO 
N2-H---OD 0.86 1.95 2.78 160.1 
N1-H---O2 0.86 2.44 3.13 137.8 
* hydrogen bond donor 





Figure 5.3. Unit cell of SMT crystal structure, seen down along the c crystallographic axis 
showing intermolecular π-π interactions. 
The asymmetric unit of SMT-DMA solvate comprises two molecules each of SMT and DMA. 
The crystal structure was solved and refined in the Pna21 orthorhombic space group. Unlike in 
the pure drug substance, the SMT molecules in the DMA solvate are held together through 
intermolecular hydrogen bonding interactions between the N1-H hydrogen bond donor and the 
S-O1/O2 acceptor. The N2-H hydrogen bond donor, which interacted with the S-O1/O2 acceptor 
in the pure drug, now participated in hydrogen bonding with the carbonyl of the DMA molecule 
in the form N2-H---O. Interestingly the tetrahedron like nature of the sulfur atom is conserved 
in the DMA solvate leaving a similar bend in the SMT molecules to that seen in the pure drug. 
However, the dihedral angle between the two ring planes is approaching perpendicularity 
(86.29°) (Table 5.3). In the DMA solvate, these “bent” SMT molecules appear to come together 
to form dimers whereby two “bent” SMT molecules assemble into a box-like structure held by 
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T-shaped π-π interactions of the two conjugated rings (Figure 5.4). The partial overlap of the 
pyrimidine rings (ring 2) and resulting π-π stacking of these rings is conserved from the crystal 
structure of the pure drug. However, in the solvate, these interactions occur along the b-axis 
and are the result of the pure SMT-SMT dimers stacking upon one and other. There is no 
stacking of ring 1 in the DMA solvate, due to the formation of the dimers through the T-shaped 
π-π interactions. 
Table 5.3. Comparison of a few parameters of SMT and its solvates. 
Parameters SMT SMT-DMF SMT-DMA SMT-DMSO 
Angle between two 
rings (o) 
75.55 88.59 86.29 89.03 
Distance between two 
rings (Å) 
5.532 4.962 4.944 5.079 
Bonding between 
SMT-SMT 
N2-H---O1/O2 N1-H---O1/O2 N1-H---O1/O2 N1-H---O1/O2 
Bonding between 
SMT-solvent 
NA N2H---OA N2H---OB/Oc N2H---OD 
 
 
The asymmetric unit of SMT-DMF solvate consists of one molecule of SMT hydrogen-bonded 
to the DMF solvent. The crystal structure belongs to P21/n monoclinic space group. The 
hydrogen-bonding network observed is similar to that in the DMA solvate i.e. N2-H is linked 
to the carbonyl of the solvent (N2H---O). The SMT molecules have a bent structure with the 
angle between the rings is approaching to perpendicularity (Table 5.3) and where the rings 1 
and 2 are separated by a distance of 4.962 Å. The view along the ‘a’ crystallographic axis 
depicts the stacking for both the ring 1 and the ring 2. The SMT molecules are aligned in the 
opposite direction unlike in the DMA solvate where they faced each other leading to a box-like 
structure discussed previously. The molecular view along b crystallographic axis (Figure 5.5a) 
depicts the same side alignment leading to a ladder-like arrangement of the SMT molecules 




Figure 5.4. Unit cell of DMA solvate seen along the b crystallographic, region to SMT dimers 
highlighted.   
The asymmetric unit of SMT-DMSO solvate comprises one molecule of SMT and one molecule 
of DMSO held by hydrogen bonds of the type N2H---O. The crystal structure belongs to P21/n 
monoclinic space group. The structural arrangement of SMT and the solvent molecules in 
DMSO solvate is similar to that in DMA solvate. The stacking of rings and the ladder-like 
arrangement exists in this solvate as well (Figure 5.5b).  
In all the solvates, the solvent molecules are engaged in strong intermolecular hydrogen 
bonding with SMT contributing to their stability. Also, the angle between two intersecting 
planes of ring 1 and ring 2 in all the solvates approaches perpendicularity (Table 5.3) as 
compared to the anhydrous SMT, where this angle is 75.55°1 and 78.1°2 as reported in the 
literature. 
 
Figure 5.5. Unit cell of DMF solvate (a) and DMSO solvate (b) seen along the b-axis, depicting 
ladder-like arrangement of SMT molecules.  
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Interestingly, in the single-component crystal systems for sulfonamide drugs (SMT, 
sulfamerazine, sulfadiazine and sulfathiazole), a recurring N-H---N hydrogen-bonding pattern 
is present between API molecules. However, in the multi-component systems for these drugs, 
this N-H---N bond is not always present. For sulfamerazine, 7 out of the 9 reported structures, 
3 out of 4 structures for sulfadiazine and all 7 structures for sulfathiazole exhibit this bonding. 
However for SMT, among the 37 structures reported, only 11 had this N-H---N bond between 
SMT molecules. In the remaining 26 multi-component crystals of SMT including the three 
solvates reported here, this bonding is absent. This N-H group in all these 26 structures is 
involved in bonding with S=O functionality of a second SMT molecule. In 12 of these cases, 
the second N-H of the amino group bonds with a hydrogen bond acceptor of the 
coformer/solvent and this is the case in 3 solvates presented here. It has not been possible to 
find a rationalization to these differences.  
The experimental PXRD patterns for the solvates corresponded to simulated PXRDs for all the 
three solvates (Figure 5.6). 
 
Figure 5.6. PXRD patterns of the three solvates. 
5.2.2 Thermal analysis, solubility and desolvation studies 
The TGA and DSC plots are shown in Figure 5.7. The ratio of SMT to solvent present in the 
crystal lattice of solvates was calculated by applying weight loss measurements to the TGA 
plots. This quantity (1:1) is in good agreement with the single crystal data (refer Table 5.4). 
DSC isotherms showed the presence of two peaks representing the loss of solvent and the 
melting of the desolvated API. The removal of the solvent in the solvate appeared at a much 
lower temperature as compared to the boiling point of the solvents (Table 5.4). The solvent 
removal peak was followed by a tiny exothermic dip signifying the rearrangement of SMT 
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molecules after solvent removal. The desolvation peaks for the three solvates appeared broad. 
DMA and DMF solvent loss occurred between 90-94°C and 102-109°C respectively. The DSC 
experiment for the DMSO solvate was performed in a different manner to ensure the entire loss 
of the solvent. It was heated to 80°C and held for 2 minutes to get rid of any DMSO trapped in 
the interstices (non-hydrogen bonded), followed by heating to 150°C and holding for 2 minutes 
to get rid of the hydrogen-bonded DMSO, it was cooled back to 80 oC and then heated to 210°C 
to account for the melting of the desolvated SMT. The solvent loss occurred between 109 and 
140 oC. An overlapping endotherm (doublet) in the region of the expected melt (Tonset = 198.5 
°C) is observed for DMSO solvate. It may suggest the presence of a small amount of chemically 
bonded DMSO remaining in the crystal structure following the heat treatment. The enthalpy of 
melting of the desolvated SMT in DMA and DMF cases was close to the literature value for 
melting enthalpy of anhydrous SMT3; the value being lower in DMSO case. The values for 
enthalpy of desolvation of solvents are lower than those of literature values of enthalpy of 
vaporization of pure solvents indicative of weaker bonding interactions between SMT-solvent 
as compared to those between solvent-solvent (Table 5.4). The order of thermal stability of the 
solvates is DMSO>DMF>DMA based on the solvent loss temperature. 
 






































(at 30oC)4, 5  
DMF 0.82 102.1 23.6 20.7 20.4 153 49.2 
DMA 1.81 90.1 20.1 23.8 23.4 165 45.2 
DMSO 15.71 109.8 40.4 21.9 21.4 189 52.1 
 
The solubility of the three solvates in their respective solvents was determined, the values for 
which are shown in Table 5.4. The order of solubility observed is DMSO>DMA>DMF. The 
solubility of the solvates is much higher as compared to the solubility of SMT in commonly 
used solvents (water, methanol, ethanol, acetone).6, 7 Exposure of the solvates to open air for a 
prolonged time (24 hours), led to their desolvation making the crystals opaque and cloudy. 
PXRD was then recorded for the opaque crystals and the diffractograms matched with that of 
pure solid SMT. VT-PXRD was carried out to study the structural changes (if any) when the 
solvent leaves. It was confirmed that the desolvated SMT molecules rearranged to the only 
stable form reported when the solvent left. Hence, these solvates could not provide a pathway 
to find a new polymorph if it existed.  
5.2.3 Raman Spectroscopy  
The Raman spectra for the anhydrous SMT and the three new solvates are depicted in Figure 
5.8. There are significant differences observed in the four spectra. A very prominent three peak 
feature below 160 cm-1 (arrow mark in Figure 5.8a) is present in the anhydrous SMT which is 
absent in all the solvates. This region usually corresponds to lattice vibrations in the crystal. 
Other spectral differences observed are discussed in the following text. For example, between 
the region 970 and 1030 cm-1 (Figure 5.8b), the anhydrous SMT shows a single peak at 997 cm-
1  with a tiny hump following it; the DMA solvate shows three peaks at 979, 993 and 1008 cm-
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1; DMF solvate has a single peak at 989 cm-1 and the DMSO solvate shows 2 peaks at 990 and 
1013.5 cm-1. Another difference in peak positions can be spotted between 1620 and 1670 cm-1 
wherein the anhydrous SMT appears at 1638 cm-1, the peak for DMA solvate moves slightly to 
1635 cm-1; the DMF solvate appears at 1654 cm-1 and the DMSO appearing at 1660 cm-1  
(Figure 5.8c). 
 
Figure 5.8. Raman spectra of SMT and its solvates. 
5.3 Conclusions 
In this study, we identified and determined the crystal structures of three new solvates 
of sulfamethazine with high boiling point solvents- dimethylacetamide, 
dimethylformamide and dimethylsulfoxide (all solvates in 1:1 stoichiometry). The 
crystal structures for the solvates were solved to be orthorhombic for DMA solvate, and 
monoclinic for DMF and DMSO solvates. Crystal structures revealed strong 
intermolecular hydrogen bonds of the type N2H---O (O belonging to the solvent) that 
bind the drug and the solvent together and impart stability to the structure. Thermal 
analysis helped in assessing the thermal stability of the solvates and the weight loss in 
the TGA experiments were in good agreement with the solvent present in the crystal 
structure of the solvates. Based on desolvation temperatures the DMSO solvate was 
found to be the most stable, followed by DMF and DMA. Desolvation of the solvates 
upon exposure to air at room temperature produced the pure solid polycrystalline SMT. 
No new polymorph of sulfamethazine was discovered through these desolvation studies. 
Since the solubility of these solvates in their solvents was quite high, they possess 
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Chapter 6. Solution and calorimetric 
thermodynamic study of a new 1:1 sulfamethazine-
3-methylsalicylic acid co-crystal 
 
A new 1:1 co-crystal between sulfamethazine (SMT) and 3-methylsalicylic acid (3mSA) was 
synthesized and its structure solved by the single crystal XRD. It was thoroughly analysed by 
various analytical techniques including PXRD, TGA and DSC. Pure co-crystal could be 
synthesized by solvent drop grinding, cooling crystallization and slurry conversion co-
crystallization. Ternary phase diagrams of this co-crystal were constructed in two solvents-
methanol and acetonitrile at 30 oC, to study the effect of solvent on the dissolution behaviour 
of co-crystals and the appearance of the solid-liquid phase diagrams. The thermodynamics of 
co-crystal formation were estimated from solubility data and calorimetric data, respectively, 
showing that formation of the SMT-3mSA co-crystal from its solid components was 
spontaneous and entropy-driven. The co-crystal formation was found to be associated with a 
5% increase in molecular volume. A relationship between the size of the region where the co-





6.1.1 Measurement of solubility 
The gravimetric technique, as explained in Chapter 4, section 4.1.2, was employed to determine 
the solubility of SMT and 3mSA in methanol and acetonitrile at 30 oC. 
6.1.2 Construction of ternary phase diagram 
The same methodology as discussed in Chapter 4, Section 4.1.3 was followed. 
6.1.3 Single crystal preparation 
The ternary phase diagram was used as guidance to identify a composition where the 1:1 co-
crystal was the most stable solid phase. SMT, 3mSA and acetonitrile were mixed in the 
corresponding ratio and the mixture was allowed to stir at 30 oC. The saturated solution was 
withdrawn with a pre-heated syringe and filtered into a preheated glass vials, and heated to 30 
oC for 30 minutes. It was then allowed to stand at 20 oC until single crystals were obtained. The 
crystals were isolated, surface dried on Whatman filter paper before PXRD analysis was carried 
out. 
6.2 Results and Discussion 
6.2.1 Solid-phase and crystal structure analysis 
The crystallographic data obtained for the 1:1 co-crystal between SMT and 3mSA are 
summarized in Table 6.1. 
Table 6.1. Crystallographic data for the 1:1 SMT-3mSA co-crystal. 
 SMT-3mSA co-crystal 
Stoichiometry 1:1 
Empirical formula C20H22N4O5S 
Formula mass 430.48 
Temperature (K) 104 
Crystal system Orthorhombic 
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Space group Pbca 
a (Å) 11.0926 (6) 
b (Å) 14.8423 (8) 
c (Å) 25.6676 (14) 
α (o) 90 
β (o) 90 
γ (o) 90 




R-factor (%) 5.35 
µ (mm-1) 0.192 
θ (max)  28.456 
Nref 5330 
Npar 274 
Goodness-of-fit (GOF) 1.159 
 
The crystal structure belongs to the Pbca space group (orthorhombic). Figure 6.1 depicts the 
molecular packing and hydrogen bond pattern present in the co-crystal. The asymmetric unit of 
the SMT-3mSA co-crystal comprising one molecule of SMT and one molecule of 3mSA is held 
by a R2
28 hydrogen bond motif between the 3mSA carboxylic acid and the amide tautomer of 
SMT. The N-H---O bond between SMT sulfonamide and 3mSA carbonyl, and the O-H---N bond 
between 3mSA hydroxyl and SMT pyrimidine nitrogen, are key components of the crystal 
structure. The phenyl ring of 3mSA shows π-π interactions with both the pyrimidine (parallel 
displacement) and phenyl ring (T-shaped) of SMT. Two SMT molecules are held together by 
hydrogen bonds of the type N-H---O. Each SMT molecule is bonded to two other SMT 
molecules and one 3mSA molecule. The dihedral angle between the two rings (phenyl and 
pyrimidine) in SMT of the co-crystal, 72.11° is close to the corresponding angle, 75.55° in pure 
SMT, which is a monomorphic system.1 The angles around the trigonal carbon in 3mSA of the 
co-crystal, 115.83° and 121.60°, are similar to those observed in pure 3mSA.2 The central ‘S’ 
atom in the SMT molecule, both in single and multicomponent crystal structures, shows 




Figure 6.1. Unit cell of the 1:1 SMT-3mSA co-crystal depicting the crystal packing and bonding 
pattern (a), hydrogen bonding forming an R22 (8) moiety in the SMT-3mSA co-crystal, distances 
in Å (b). 
The optical micrograph of the co-crystal single crystal shows a plate-like crystal habit as seen in 
Figure 6.2. 
 
Figure 6.2. Micrograph obtained by optical microscopy of a single SMT-3mSA co-crystal. 
The experimental PXRD pattern recorded for the co-crystal matches well with the simulated 
PXRD pattern obtained using Mercury from the crystal structure determined by the single-
crystal XRD (Figure 6.3a). In addition, the co-crystal pattern is unique as compared to the pure 





Figure 6.3. Experimental and simulated PXRD patterns for the 1:1 SMT-3mSA co-crystal (a); 
Comparison of PXRD patterns between the SMT-3mSA co-crystal with SMT and 3mSA (b). 
The crystal structure determination suggests that the solid is a co-crystal as opposed to a salt. 
The two C-O bond lengths for the carboxylate group of the coformer, 3mSA are 1.242 and 
1.302 Å, bringing the difference to 0.06 Å. This is similar to the case of the SMT-salicylic acid 
co-crystal, where the difference between the two C-O bond lengths is 0.049 Å (GEYSAE). For 
salts, this difference is usually less than 0.03 Å as the carboxylate ion, formed after proton loss 
goes into resonance.3 Using 2.654 as pK1 value for the conjugate acid form of the basic SMT 
and 2.955 as pK1 value for 3mSA, ∆pKa becomes -0.3, which according to the pKa rule also 
suggests that SMT-3mSA should form a co-crystal as opposed to a salt.6 These pKa values arise 
from the amino functional group of the basic API and carboxylic group of the acidic coformer. 
The interactions in the co-crystal occur through the sulfonamide group of the API and the 
carboxylic group of the coformer. It is interesting to note that the amino group, based on which 
the pKa rule is applied does not interact with the coformer. The geometric and steric factors 
ensure that the system assembles in a way to minimize the free energy. This indicates that, 
although the pKa rule can act as a guide in predicting whether a salt or co-crystal will form, it 
is not completely reliable.  
6.2.2 Thermal analysis and solid phase thermodynamics 
TGA curves for the three solid phases SMT, 3mSA and the co-crystal are presented in Figure 
6.4. There is no indication of any bound solvent in either of the solids. For3mSA,, the mass starts 
to decrease at around 420 K, and at 500 K, virtually all the 3mSA has been lost, due to 




with an onset of mass loss at approximately 440 K. At 520 K, there is a slight change in the 
slope of the co-crystal TGA curve, and by then 35% of the initial mass is lost, corresponding to 
the loss of 1 molecule of 3mSA from the 1:1 co-crystal; the molar masses of SMT and 3mSA 
being 278.33 g/mol and 152.15 g/mol, respectively. This temperature corresponds well to the 
point where the TGA curve for pure SMT begins to decrease. Both the SMT and the co-crystal 
curves then proceed to further decay in a similar fashion. 
 




Figure 6.5. DSC thermograms of the 1:1 SMT-3mSA co-crystal, the pure components (SMT 
and 3mSA) and an equimolar physical mixture of the solid components.  
The DSC traces for the pure co-crystal and for the two respective starting components in the 
pure state each show a single endothermic melting peak; Figure 6.5. The extrapolated melting 
temperatures and the associated enthalpies of fusion of the co-crystal and 3mSA were 
determined as averages of either 4 or 5 repeat DSC runs. The data is given in Table 6.2 together 
with data for SMT from previous work. The melting point of the co-crystal (453.0 K) is 
intermediate between that of pure SMT (469.7 K) and pure 3mSA (436.5 K). Notably, the molar 
values of the enthalpy and entropy of fusion for the co-crystal are significantly higher than for 
the pure components, but the sum of the values of the pure components exceeds the value for 
the co-crystal, both with respect to enthalpy (5.2 kJ/mol) and entropy (10.5 J.(mol.K)). Please 
note that one mole of co-crystal consists of one mole each of API and coformer. This suggests 
that the co-crystal has a higher, less favourable enthalpy than the sum of its components, but 
also a higher, more favourable entropy. However, since these phase transitions occur at different 
temperatures, an exact comparison cannot be done without making temperature corrections 
using heat capacity data. 
Table 6.2. Melting point data for the three pure solids SMT, 3mSA and the co-crystal, together 
with standard errors over N repeat experiments. 
 Sulfamethazine 3-methylsalicylic acid 1:1 co-crystal  
Tm / K [N] 469.66 ± 0.03 [4] 436.5 ± 0.21 [4] 453.04 ± 0.09 [5] 
∆fusH (Tm) / kJ·mol-1 36.0 ± 0.14 25.71 ± 0.09 56.6 ± 0.19 
∆fusS (Tm) / J·K-1·mol-1 76.7 ± 0.30 58.9 ± 0.22 125.0 ± 0.42 
 
The DSC thermogram for the equimolar physical mixture of API and coformer (Figure 6.5) 
exhibits two discrete endothermic peaks, The first is a faint endothermic event (shown in inset) 
with an onset at 406 K (standard error = 1.3 K) and an enthalpy of 6.6 kJ/mol (standard error = 
0.11 kJ/mol), as averaged over four repeat scans. This is followed by a melting peak that 
matches the melting peak of the co-crystal with respect to both onset temperature and enthalpy 
to within the levels of experimental uncertainty. From this, it may be concluded that the 
endotherm at 406 K corresponds to the spontaneous, solid-solid transformation of the equimolar 
mechanical mixture into the co-crystal. 
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The Gibbs energy of formation of a solid co-crystal (AB), ΔAB
form𝐺 at temperature T in relation 








      
A negative Gibbs energy of co-crystal formation signifies that the molecular-level process of 
mixing equal parts of the two solid components and forming the co-crystal structure is 
spontaneous. ∆formABG consists of an enthalpic and an entropic component. Generally, the 
enthalpy term is expected to be negative, indicating increased bonding in the co-crystal, and 
favouring co-crystal formation, while the entropy term often appears to be negative, working 
against co-crystal formation.7-10  
Occasionally,11 notably including the 1:1 co-crystal between SMT and salicylic acid (SA), a 
reverse relationship is observed, meaning the process of co-crystal formation is endothermic,  
and an increase in entropy drives the process. As can be directly observed, cf. the thermograms 
in Figure 6.5, the formation of the 1:1 SMT-3mSA co-crystal from an equimolar mixture of API 
and coformer is endothermic at elevated temperatures (6.6 kJ/mol at 406 K). However, the co-
crystal formation still occurs spontaneously at 406 K. This shows that the total Gibbs energy of 
formation is negative, and that the process accordingly has to be driven by a favorable (negative) 
entropy change, similarly as for the 1:1 SMT-SA co-crystal.  
The entropy increase occasionally observed in co-crystal formation has been proposed to be 
associated with a volume increase.7, 12  If one molecule of co-crystal (AB) is defined as one 
molecule of each component (A and B), the increase in molecular volume can be calculated as:  
Equation 6.2 
cell cell cell
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 
 
where Zi denotes the number of molecules in the unit cell of i. Using data from the Cambridge 
structural database for the structures SLFNMD10 (SMT),1 CRESOT10 (3mSA)2 and comparing 
with the structural data for the co-crystal, Table 6.1, the increase in molecular volume on co-
crystal formation was estimated to 26.3 Å3 per co-crystal “1:1 molecule”, or 5%. Notably, the 
data for the structures of the solid API and coformer is valid at room temperature (283-303 K), 
while the data for the co-crystal was collected at 104 K. Given a positive thermal expansion 
coefficient, both the unit cell volume of the co-crystal at 293 K and the true expansion on co-
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crystal formation at this temperature would be even larger. It has been suggested that an 
increased degree of hydrogen bonding often serves to counteract close packing and accordingly 
results in a volume increase.13 A comparison of the three respective crystal structures shows that 
the SMT molecule is able to participate in additional hydrogen bonding interactions within the 
co-crystal lattice compared to in the pure component crystal structure. 
6.2.3 Solubility and phase diagrams 
The solubility data for SMT and 3mSA in acetonitrile and methanol at 30 oC are listed in Table 
6.3. In both solvents, the coformer, 3mSA is significantly more soluble than the API, SMT. The 
solubility ratio of 3mSA to SMT in methanol (41.7) is notably higher than in acetonitrile (6.2). 
Table 6.3. Solubility of sulfamethazine (SMT) and 3-methylsalicylic acid (3mSA) in methanol 
and acetonitrile at 30 oC. 
Solvent 
Solubility (mol/L) Solubility ratio 
(3mSA/SMT) 
Dissolution 
behaviour SMT 3mSA 
Acetonitrile 0.0592 0.3675 41.7 Incongruent 
Methanol 0.0650 2.7121 6.2 Incongruent 
 
The ternary phase diagrams for the 1:1 SMT-3mSA co-crystal in acetonitrile and methanol are 
depicted in Figure 6.6 and Figure 6.7, respectively. The choice of mass fraction over mole 
fraction was made to enhance the visibility of the solubility curves in the ternary phase diagrams. 
The 1:1 stoichiometric line does not intersect the co-crystal solubility curve and accordingly the 
co-crystal shows incongruent dissolution in both solvents. Additional slurry experiments 
confirmed the nature of incongruent dissolution for the SMT-3mSA co-crystal. In both solvents, 
excess of pure co-crystal transformed to a mixture of SMT and co-crystal. In methanol, with a 
higher solubility ratio of coformer to API, the co-crystal region in the ternary phase diagram is 
skewed more towards the more soluble component 3mSA side, and is very narrow. In 
acetonitrile, the co-crystal region is broader, although still skewed towards the coformer side. 
The invariant points are the solution concentrations at which two solid phases are stable and 
simultaneously in equilibrium with the solution. The compositions in mole fractions are given 
in Table 6.3. The phase diagrams in Figure 6.8 show the incongruent nature in the two solvents 
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and highlight the contrast in the sizes of regions where the co-crystal is stable. Dissolution of 
the pure 1:1 co-crystal in either solvent is thermodynamically expected to lead to the formation 
of solid SMT or a mixture of SMT and co-crystal depending on the quantity of solvent and extent 
of dissolution. Likewise, evaporation of a solution at 30 oC containing a stoichiometric 1:1 
mixture of SMT and 3mSA in methanol or acetonitrile would not (from a thermodynamic point 
of view) lead to the formation of pure co-crystal. This can be analysed by following the 1:1 
stoichiometric line joining the solvent vertex and the 1:1 co-crystal composition point on the 
SMT-3mSA axis. Since in both solvents the stoichiometric line crosses through regions ‘2’ and 
‘3’, formation of either solid SMT or a mixture of SMT and co-crystal is to be expected, 
depending on the evaporation end point. 
 
Figure 6.6. Full scale (left) and zoom-in view of ternary phase diagram of SMT-3mSA co-
crystal system in acetonitrile at 30 oC. Values are in mass fractions. The blue dotted line is the 
1:1 molar stoichiometric line. Regions in the diagram are as follows: (1) solution phase; all other 
regions consist of a saturated solution in contact with (2) SMT, (3) SMT + co-crystal (green 
filled circles), (4) 3mSA + co-crystal (purple inverted triangles), (5) 3mSA, (6) co-crystal (red 





Figure 6.7. Full scale (left) and zoom-in view of the ternary phase diagram of SMT-3mSA co-
crystal system in methanol at 30 oC. Values are in mass fractions. The blue dotted line is the 1:1 
molar stoichiometric line. Regions and various points are same as marked in Figure 6.6. 
 
Figure 6.8. Phase diagram of SMT-3mSA system in acetonitrile (a), and methanol (b). The 
horizontal green line corresponds to the solubility of pure SMT at 30 oC in each solvent. The 
points (filled circles) depict the invariant points at the same temperature. The blue dotted line 
is the 1:1 stoichiometric line. 
Since in both solvents the co-crystal dissolves incongruently, co-crystal solubility determination 
via traditional techniques such as gravimetry is not possible as it relies on establishment of 
thermodynamic equilibrium between the solution and the co-crystal. However, in both solvents, 
we observe from Figure 6.8, that the SMT solution concentration at the invariant point with solid 




SMT. Accordingly, dissolution of the pure 1:1 co-crystal in either solvent will lead to a solution 
having a higher SMT concentration than that obtained by dissolving pure solid SMT. 
Accordingly, from a pharmaceutical preformulation point of view the co-crystal will potentially 
lead to a higher dissolution rate and thus potentially a higher bioavailability. 
From a co-crystal manufacturing point of view, the pure SMT-3mSA co-crystal, in spite of the 
incongruency, can still be obtained by slurry conversion crystallization from a physical mixture 
of the two solid components in the solvent, if the overall composition is in the co-crystal region 
(region 6) of the phase diagram (Figures 6.6 and 6.7). This requires, an initial excess addition of 
the more soluble 3mSA than SMT, to place the conditions on the solubility curve of the co-
crystal, then followed by addition of a suitable stoichiometric amount of each of the two pure 
solid components. The co-crystal formation can be initiated by addition of a smaller amount of 
co-crystal seeds. 
Table 6.4. Equilibrium solution concentrations of SMT and 3mSA for different solid phases at 
equilibrium with acetonitrile and methanol. 
Solvent 
Solid phase at 
equilibrium 
Invariant points (Mole fraction) 
Ksp (M2) 
SMT 3mSA Solvent 
Acetonitrile 
SMT + co-crystal 0.0041 0.0055 0.9903 8.0x10-3 
3mSA + co-crystal 0.0013 0.0211 0.9775 1.1x10-2 
co-crystal 0.0016 0.0122 0.9861 7.6x10-3 
Methanol 
SMT + co-crystal 0.0027 0.0125 0.9848 2.1x10-2 
3mSA + co-crystal 0.0025 0.0144 0.9730 2.3x10-2 
 
The Ksp values in methanol and acetonitrile are given in Table 6.4 as calculated from the data of 
the invariant points. Notably, it is higher in methanol than in acetonitrile, signifying a higher co-
crystal solubility in methanol. 
Equation 2.19 can be used to estimate the Gibbs energy of co-crystal formation of solid co-
crystal from its pure, solid components. Using the average Ksp values (see Table 6.4), the Gibbs 
energies of co-crystal formation from methanol and acetonitrile become -2.3 kJ/mol and -5.0 
kJ/mol, respectively. The negative values reveal that co-crystal formation from its pure 
80 
 
components is a thermodynamically favored process. At high temperature (406 K), the 
spontaneity of co-crystal formation has indeed been confirmed by DSC (Figure 6.4). 
As is shown in Table 6.5, the solubility ratio of the pure co-crystal components, i.e coformer to 
API solubility, cannot be used to predict whether the co-crystal will dissolve congruently or 
incongruently. 
With the change in solvent, the size of the region where co-crystal is the most stable solid phase 
changes appreciably. The size of this region can be estimated in terms of the area of a triangle, 
given by Heron’s formula (Equation 6.3). In Figure 6.9b, the three vertices of the triangle in the 
ternary phase diagram are the stochiometric point (R) and the two invariant points (P and Q); 
the coordinates represented as x, y, and z. Using the 3D-distance equation (Equation 6.4), the 
lengths (d) of the edges ‘PQ’, ‘QR’, and ‘PR’ denoted as ‘da’, ‘db’, and ‘dc’ respectively can be 
determined, which in turn can be used to determine the area ‘A’ represented by the purple region 
in Figure 6.9b. Notably, the curvature of the co-crystal solubility line between the two invariant 
points, is neglected. Solubility ratio, denoted as ‘r’ referes to the coformer to API solubility ratio. 
The linear best fit between log (A) and log (r) is shown in the schematic in Figure 6.9a. The 
regression coefficient, 0.94 depicts the linearity of the data. In Figure 6.9a, data from an 
additional system, SMT-salicylic acid in methanol, acetonitrile and DMSO-methanol is 
included. An inverse relationship between ‘r’ and ‘A’, meaning a high coformer to API solubility 
ratio leads to a small co-crystal region and a low solubility ratio leads to a big co-crystal region 
in the ternary phase diagram. 
Table 6.5. The dissolution behavior of two sulfamethazine co-crystals in different solvents.  









Acetonitrile 6.2 Incongruent 




Acetonitrile 11.5 Congruent 
Methanol 61.8 Incongruent 






𝑎 + 𝑏 + 𝑐
2
, 𝐴 = √𝑠(𝑠 − 𝑑𝑎)(𝑠 − 𝑑𝑏)(𝑠 − 𝑑𝑐) 





Figure 6.9. Plot of log A (area of region in ternary phase diagram where co-crystal is the stable 
solid phase) vs. log r (ratio of coformer to API solubility). Red symbols correspond to the SMT-
salicylic acid co-crystal; blue symbols correspond to the SMT-3mSA co-crystal; different shapes 
represent different solvents (a); schematic representing the three vertices of the triangle P, Q, R; 
purple coloured region represents the area of the triangle (b).  
6.3 Conclusions 
A new 1:1 co-crystal between sulfamethazine and 3-methylsalicylic acid has been synthesized. 





ternary phase diagrams have been constructed in methanol and acetonitrile. The co-crystal 
exhibits incongruent dissolution in both solvents. Co-crystal formation from its solid 
components is shown to be spontaneous, with a negative Gibbs energy change, and endothermic, 
and hence driven by entropy increase. It is accompanied by at least a 5% increase in molecular 
volume. The melting point of the co-crystal is 453.0 K, which is between the melting points of 
the pure API and coformer. The enthalpy of fusion of the co-crystal is 56.6 kJ/mol, higher than 
that of both the API and coformer. The size of the co-crystal region is inversely proportional to 
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Chapter 7. Microwave assisted slurry conversion 
crystallization for manufacturing of new co-




In this work, the ability of microwave-assisted slurry conversion co-crystallization has been 
evaluated by using two structurally similar sulfa drugs, sulfamethazine (SMT) and 
sulfamerazine (SMR) as model compounds. We show by comparison with normal 
conductive/convective heating to the same temperature that the microwave heating is much 
more efficient in promoting the formation of co-crystals. It is found that the microwave 
radiation heating makes the formation of the co-crystals much faster, likely to be related to the 
molecular structuring associated with the microwave radiation. It is also shown that microwave-
assisted co-crystallization can be scaled up to efficiently produce larger quantities of co-crystal 
material. In this process, three new co-crystals, SMT-NIC, SMR-SAL and SMR-AA were 
discovered and were characterized by analytical techniques. The crystal structures are 
discussed. The co-crystals have a higher equilibrium concentration of the drug compared to 
pure solid APIs. Co-crystals seem to be stable under ambient and high temperature and 
humidity conditions. By Hirshfeld analysis and interaction energy calculations, the difference 
in stability, reactivity and rate of formation of co-crystals of sulfamethazine and sulfamerazine 
can be explained.  
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7.1 Experimental work 
7.1.1 Microwave reactor 
A precisely controlled Ultrasound and Microwave Automatic Reactor, ATPIO XO-SM100, 0-
1000W, was used as a source for microwave irradiation. The crystallization experiments were 
performed in 30 mL glass vials for 0.2 and 2 g scales with agitation provided by magnetic stir 
bars of the size 1.27 cm by 0.32 cm (0.5 by 0.125 in). For 20 g scale, the experiments were 
performed in 100 mL Duran lab bottles using magnetic stir bars of the size 2.5 cm by 10 cm. 
The microwaves were used as the heating source to maintain the crystal slurry at elevated 
temperature.  
7.1.2 Co-crystal manufacturing 
7.1.2.1 Microwave assisted slurry conversion crystallization 
Equimolar amounts (0.5 mmol) of API and coformer (~ 0.2 g) were mixed with 1 mL 
acetonitrile (See Table 7.1 for amounts) in 30 mL glass vials. The experiments were operated 
at a constant temperature using a microwave radiation power of max 500 W. The microwave 
apparatus automatically adjusts the actual power used to heat up to the desired temperature and 
to maintain that temperature for the desired time. The slurry conversion progress was traced by 
taking samples for PXRD analysis. During sampling, the microwave radiation and the stirring 
had to be turned off. Accordingly, introductory experiments were performed to establish the 
time needed to obtain complete conversion of the slurry into pure co-crystal material. This 
involved running the experiment for a specific time, turn off heating and agitation to take a 
sample, and then starting up again to continue for another period of time, etc. These steps were 
repeated until co-crystal was obtained. When the time required had been established by the 
introductory experiments (around 4 minutes at 70 oC), confirmation experiments were operated 
without interruption until the end of the particular experiment.  
Experiments with microwave irradiation were performed at 70 oC for 4 minutes under 
continuous stirring at 120 rpm. The instrument provides and adjusts the irradiation power to 
maintain the set temperature (70 oC). The magnetic stir bar was fully immersed in the mixture. 
A thermocouple was dipped into the slurry to record the temperature. After 4 minutes the solid 
was filtered and characterized by PXRD. If the PXRD pattern was unique as compared to its 
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components, single crystals were grown. Powders were further characterized by techniques like 
TGA, DSC, Raman and FT-IR spectroscopy.  
7.1.2.2 Conventional heated slurry conversion crystallization 
The slurry conversion crystallization was performed using indirect heating by the jacket instead 
of using microwaves, keeping all other parameters same. In 30 mL glass vials, API, coformer 
and solvent were mixed as above, the mix was subjected to stirring at 70 oC, 120 rpm using the 
same kind of the magnetic stir bar. Small amounts of samples were withdrawn to check for co-
crystal formation by PXRD at different time intervals ranging from 4 minutes to 24 hours. For 
the case (SMR-SAL) that did not form even after 24 hours, the next sampling was done at 48 
hours.  
7.1.2.3 Single crystal preparation 
Cooling crystallization was employed in order to obtain large single crystals for structural 
determination. Same technique as described in section 5.1.1 was used, the only difference being 
that the solution was seeded with ~1% w/w (seed mass/mass to be crystallized) with a seed size 
distribution of 5-30 µm. The co-crystal seeds were obtained from microwave slurry 
crystallization experiments. 
7.1.3 Scale-up studies and process experiments 
Microwave-assisted co-crystallization was used to synthesize the three new co-crystals at ~ 2 g 
scale and ~ 20 g scales i.e. 10 and 100  fold increase respectively (See Table 7.2 for amounts). 
In glass vials, the required amounts of the starting material were mixed with acetonitrile to form 
slurries. Under continuous stirring, they were subject to microwave irradiation at 70 oC, 500 W 
for 4 minutes. The solids were filtered and allowed to dry. They were then characterised by 
PXRD. The co-crystal yield was calculated as the mass of co-crystal obtained divided by the 
total API and coformer mass used; volumetric productivity was calculated as the mass of the 
co-crystal obtained divided by the total slurry volume. 
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7.1.4 Equilibrium experiments 
Solubility experiments were performed to determine the solubility of pure APIs. Co-crystal 
material was equilibrated with water to determine the API equilibrium concentration. For a 
congruent system that equilibrium concentration equals the solubility of the co-crystal. For an 
incongruent system, the equilibrium solid phase is either a mixture of co-crystal and pure 
compound at which the equilibrium concentration corresponds to the eutectic point, or is pure 
compound only and then reflects the solubility of the pure compound in a solution also 
containing dissolved coformer. The solid phases added for solubility experiments were form I 
each for SMT and SMR. For equilibrium experiments, the as-synthesized co-crystals of SMT-
NIC, SMR-SAL and SMR-AA were charged into water. The PXRD of the solids after the 
equilibration was determined to observe any phase transformations. The same form as added 
was returned for single component APIs, SMT and SMR (form I each). For co-crystals, only 
SMR-AA gave the same solid form as the one started with, signifying congruent dissolution. 
For SMT-NIC and SMR-SAL, the solid forms obtained were pure SMT, and SMR and SMR-
SAL mixture respectively, suggesting that the dissolution was incongruent. 
HPLC analysis was performed to determine the concentration of API in the equilibrium 
experiments. Methanol/2% acetic acid (50/50, v/v) as the mobile phase at a flow rate of 
1mL/min. The two components of the co-crystals in all cases were well separated. The first step 
required the construction of calibration line graphs between peak area and concentration in g 
API per mL by preparing stock solutions of known concentrations of SMT and SMR. The 
calibration lines depicted good linearity (R2 = 0.99). The second step required the preparation 
of saturated solutions for each of the samples at 25 oC. Excess solid was charged to ~ 5 mL 
water and left under continuous agitation for 3 days to achieve equilibrium. The stirring was 
stopped and the samples were filtered and diluted before analysis. Vials, syringes and filters 
were pre-heated before sampling. The peak areas of diluted samples obtained from HPLC were 
used to determine the saturated concentrations from the calibration curves, considering the 
dilution factor. Three separate experiments were performed for each system. The uncertainty in 
the calculated mole fraction for all samples is < 0.0008. 
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7.1.5 Stability studies  
Each co-crystal sample was stored in a desiccator filled with saturated sodium chloride solution 
to maintain 75 % relative humidity (RH). The temperature was maintained at 40 oC and co-
crystal samples were analysed by PXRD after 1 day, 1 week and 9 weeks. The co-crystal 
samples left in the lab cupboard for 6 months in glass vials were analysed by PXRD. The lab 
conditions for relative humidity and temperature are 51±3 % RH and 20±3 oC. 
7.1.6 Hirshfeld surface analysis and interaction energy calculations 
Hirshfeld surface analysis is useful in describing and visualizing the overall molecular 
interactions present in any crystal structure quantitatively.1, 2 The Hirshfeld surfaces and their 
2-D fingerprint plots were generated for each symmetry independent molecule in the three new 
co-crystals, SMT-NIC, SMR-SAL and SMR-AA and their components using the Crystal 
Explorer 17.5 software.3  
Using the same software package, interaction energy was estimated for all the crystal structures 
using the crystallographic input file (cif). The energy calculations were carried out at the 
B3LYP/6-31G (d,p) molecular wavefunction level for all the symmetry independent molecules. 
For crystal structures having two symmetry independent molecules, the energy calculations 
were performed for each molecule, one at a time, by constructing a 3.8 Å cluster around each 
molecule. For co-crystals, an additional step of calculating the energy of the molecular pair was 
performed before creating clusters. The components for interaction energy include electrostatic, 
polarization, dispersion and exchange-repulsion, which are related to the total energy as per 
Equation A.1, explained in Appendix. 
7.2 Results and Discussion 
7.2.1 Slurry conversion experiments 
Co-crystal formation ability of SMT and SMR was investigated for a series of coformers as 
summarised in Table 7.1. All the previously reported co-crystals could be successfully 
reproduced by microwave-assisted slurry conversion within 4 minutes at 70 oC. For the cases 
where co-crystal formation failed, no such co-crystals have been reported in the literature. 
Moreover, three novel co-crystals (SMT-NIC, SMR-AA, SMR-SAL) were obtained. Notably, 
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an SMT-NIC co-crystal has been reported previously (E. Lu et al. 39) but the PXRD pattern and 
the melting temperature provided do not match with our data, perhaps suggesting a different co-
crystal solid form.  
Compared to 4 minutes required for the production of the three new co-crystals by microwave 
heating, conventional heated slurry conversion crystallization could only produce the SMT-NIC 
co-crystal within the same time. Manufacturing of the SMR-AA co-crystal required as a 
minimum 8 h, and for the SMR-SAL co-crystal formation not even 24 h was sufficient. 
Obviously, the microwave heating increases the rate by which co-crystals form confirming that 
the optimization of the synthetic conditions is critical to the successful isolation of the desired 
product. 













0.0690 S Published (GEYSAE) 
NIC 0.0610 S New 
AA 0.0685 S Published (SORWEB) 
BEN 0.0605 S Published (EXAPAV) 
ASP 0.0900 S Published (VUGMIT) 




0.0690 F - 
NIC 0.0610 F - 
AA 0.0685 S New 
BEN 0.0605 F - 
ASP 0.0900 F - 
SAL 0.0685 S New 
*S: Success, F: Failure 
 
7.2.2 Scale-up studies  
Under the same microwave conditions used for synthesizing co-crystals at ~ 0.2 g scale at 70 
oC, 4 minutes were enough to produce pure co-crystals in acetonitrile for all three new co-crystal 
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forms at 2 g and 20 g-scale. The yield and volumetric productivity of the process have not been 
optimised. The results are given in Table 7.2, highlighting the potential of this technique for 
producing larger quantities of pure co-crystal. It is known that using microwave heating at a 
larger scale is associated with limitations in microwave penetration,4 degradation or 
decomposition of reactants or products and safety implication due to pressure build-up.5 These 
problems were not observed in the present work, because of rapid mixing, and adequate 
temperature control.6, 7 Increase to even larger scale may however require consideration of these 
conditions and continuous flow-through systems can be advantageous. 
Table 7.2. Mass of input reagents for microwave-assisted scale-up co-crystallization 
experiments, co-crystal yield and volumetric productivity 
Co-crystal 
Input reagents  Output reagent (Co-crystal) 
API Coformer Solvent Mass Yield Volumetric Productivity 
(g) (mL) (g) (%) (g/mL) 
SMT-NIC 
1.391 0.610 3 1.9235 96.1 0.43 
13.91 6.100 30 19.3599 96.7 0.44 
SMR-SAL 
1.321 0.685 3 1.9265 96.0 0.43 
13.21 6.850 30 19.6222 97.8 0.44 
SMR-AA 
1.321 0.685 3 1.9545 97.4 0.44 
13.21 6.850 30 19.6352 97.8 0.44 
7.2.3 Mechanism 
It has been suggested that the solvent acts as a lubricant and provides a medium to enhance co-
crystal formation by liquid assisted grinding.8, 9 In this view the solvent provides kinetic 
enhancement i.e. increased possibility of molecular collisions caused by additional degrees of 
freedom for molecules. In the conventional slurry conversion method, the rate depends on the 
solubility driving force, relative concentrations of the API and coformer, and nucleation and 
growth kinetics of the system.10 In microwave-assisted slurry crystallization, microwave-
91 
 
heating increases the molecular movements, enhancing the opportunities for molecular 
collisions and interactions between solute and solvent molecules. In particular, the microwave 
irradiation promotes an ordering and alignment of molecules with a frequency of the 
electromagnetic field, which probably is an important reason for the more rapid formation of 
the co-crystal.  
7.2.4 Sulfamethazine v/s sulfamerazine reactivity  
The two sulfa drugs, SMT and SMR are structurally similar, the only difference being the lack 
of methyl group on the pyrimidine ring in SMR. SMT and SMR have the same type and number 
of hydrogen bond donors and acceptors however exhibit a different hydrogen-bonding pattern.11 
In this study, SMT shows a higher tendency to form co-crystals as compared to SMR, which 
agrees with previous findings12, 13 and explained by the difference in geometric fit and steric 
hindrance towards coformers in forming new solid forms (co-crystals). The asymmetric unit of 
SMR shows two SMR molecules held together by an R2
28 hydrogen bond motif, which lacks in 
SMT. This explains more stable crystal structure of SMR as compared to that of SMT. This was 
also reflected in the thermal analysis wherein SMR had a higher melting point compared to SMT 
(Table 7.5) and supported by the interaction energy calculations, discussed later. 
7.2.5 Solid Phase and Crystal Structure Analysis 
The crystallographic data obtained for the new co-crystal systems are summarized in Table 7.3. 
For each of these co-crystals, there was a good correlation between the calculated PXRD pattern 
obtained from SC-XRD and the experimental PXRD pattern. Besides, the patterns are unique as 
compared to the starting components confirming the formation of a new phase i.e. co-crystal 




Figure 7.1. The dimers of SMT (left) and SMR polymorph I (right) depicting the hydrogen 
bonds; obtained from CSD. 
SMT exists as a single polycrystalline form (form I). The crystal structure consists of two 
hydrogen bonds of the type (sulfonamide) N1-H---O1 (sulfonyl) (see Figure 7.1, left) and (amino) 
N1-H---N3/N4 (pyrimidine). Each SMT molecule is bent around the sulfonamide functional 
group such that the angle between the two rings is ~ 75.55o. 
There are three polymorphs for SMR reported in literature.14-16 Two of these (Polymorphs I and 
II) are in an enantiotropic relationship and both have an orthorhombic structure crystallizing in 
the Pn21a and Pbca space groups respectively. The transformation between Polymorphs I and 
II takes place at ~ 422 K.14 Polymorph III crystallizes in the monoclinic crystal system. The 
SMR molecule can rotate around the sulfonamide moiety to give rise to a number of 
conformations. There are no major differences in the bond lengths or angles in the three forms. 
The dihedral angle between the two rings: phenyl and pyrimidine in form I, II and III are 75.8, 
83.4 and 83.5o respectively. Similar types of hydrogen bonds hold two SMR molecules in all 
three forms. The starting material used in this work is polymorph I, the crystal structure for 
which shows two SMR molecules held by hydrogen bonds of the type (sulfonamide, molecule 
I) N2-H---N8 (pyrimidine, molecule II); (sulfonamide, molecule II) N6-H---N4 (pyrimidine, 
molecule I) and (amino) N5-H---O5 (sulfonamide) (see Figure 7.1, right). The central sulphur 
atom shows a tetrahedral nature where the central angle (N-S-C) in the three polymorphs I, II 
and III correspond to ~107, 108 and 106o respectively. 
N-substituted secondary sulfonamide molecules exhibit tautomerism. In particular, amidine and 
imidine forms are known. Since the amidine tautomer is more stable than the imidine tautomer,17 
pure SMT exists in the amidine form.18 However, in the presence of certain coformers (generally 
amides), the less stable imidine tautomer form of the sulfonamide may be stabilized.19 Besides 




Figure 7.2. Unit cell of the SMT-NIC co-crystal (left) and SMR-AA co-crystal crystal structure 
showing hydrogen bonds (right). 
a) Sulfamethazine-Nicotinamide (SMT-NIC): The crystal structure of the SMT-NIC co-crystal 
belongs to the P21/c monoclinic space group; crystallographic data are presented in Table 7.3. 
The asymmetric unit comprises one SMT and one NIC moiety held together by a R2
28 hydrogen 
bond motif between the amide and the imidine tautomer (Figure 7.2, left). Such dimer is further 
arranged into a chain through a N-H---N bond between the API’s amine and the pyridine of the 
coformer. Adjacent chains are stabilised by interactions between two SMT molecules (amine-
sulfonamide N-H---O). The dihedral angle between the two pyrimidine and pyridine rings is 
approaching perpendicularity (~89o). This trend has previously been observed in other multi-
component SMT systems. The pyridine ring in nicotinamide depicts π-π interactions with the 
phenyl ring of one SMT molecule and the pyrimidine ring of another SMT, separated by 3.553 
and 3.703 Å respectively. There are two types of stacking in the crystal structure, one between 
the NIC molecules and the other being bent SMT molecules with stacked pyrimidine rings. Two 
consecutive SMT molecules and NIC molecules are separated by a distance of 8.351 Å. 
b) Sulfamerazine-Anthranilic acid (SMR-AA): The 1:1 co-crystal crystallizes in P-1 triclinic 
space group and the crystallographic data are given in Table 7.3. Each asymmetric unit consists 
of one SMR and one AA that are held together by an R2
28 hydrogen bond motif between the 
carboxylic acid and the amidine tautomer (Figure 7.2, right). Two of such hetero-molecular 
dimers interact through a pair of N-H---O H-bond between the coformer’s amine and the API’s 
sulfonic oxygen. Finally, two SMR molecules form another homomolecular dimer sustained by 
amine-pyrimidine N-H---N bond and a π-π stacking between two phenyl rings. The angle 
between the two rings of SMR is 83.96o, which is not too far from that in pure SMR. The phenyl 
ring of the AA molecules is parallel to the pyrimidine ring of the SMT molecule, separated by 
3.588 Å. SMR takes an L-shaped conformation with the tetrahedral geometry around the sulphur 
atom conserved, the angle being 107.28o. The crystal structure of this co-crystal consists of bent 
SMR molecules facing each other with AA molecules present parallel in the space between 
them. 
c) Sulfamerazine-Salicylamide (SMR-SAL): SMR and SAL crystallize in the P-1 space group 
with one independent molecule in the asymmetric unit, crystallographic data are given in Table 
7.3. The API is present in the amidine tautomer, which forms a homomolecular dimer through 
a centre of inversion via an R2
28 hydrogen bond motif. Another R2
28 hydrogen bond motif is 
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recognized between the amide moieties of two salicylamide molecules. The three-dimensional 
structure is sustained by N-H---O bonds between the SAL amine and the sulfonic group, whereas 
the SMR amine donates into the hydroxyl oxygen. The dihedral angle between two rings in the 
SMR molecule of the co-crystal is 87.02o, higher than that in pure SMR. The angle around the 
sulfur atom (∠C9SN7) is 107.34o, close to the one in pure SMR. Two ‘L’ shaped bent SMR 
molecules face each other to form box-like structures reported earlier (Figure 7.3, left). These 
box-like structures have pyrimidine rings separated by 3.63 Å suggesting π-π interactions 
between them. The crystal structure has parallel lanes of SAL molecules aligned in the opposite 
direction and separated by a distance of ~4.0 Å (Figure 7.3, right). 
 
 
Figure 7.3. Unit cell of SMR-SAL co-crystal depicting the two types of eight-membered ring 
synthons (left), crystal arrangement depicting parallel lanes of SAL molecules (right); blue: 





Figure 7.4. PXRD pattern of the new co-crystals prepared by microwave-assisted slurry 
conversion (microwave) and liquid assisted grinding (LAG) in comparison with the pure 
components and the simulated pattern 
 
Figure 7.5. Optical micrographs of single crystals of SMR-SAL co-crystal (a), SMR-AA co-




Table 7.3. Crystallographic data for the three new co-crystals. 
 SMR-SAL SMT-NIC SMR-AA 
Stoichiometry 1:1 1:1 1:1 
Chemical formula C11H12N4O2S.C7H7NO2 C12H14N4O2S.C6H6N2O C11H12N4O2S.C7H7NO2 
Formula mass 401.44 400.46 401.44 
Temperature (K) 100 298 296 
Crystal system Triclinic Monoclinic  Triclinic 
Space group P -1 P21/c P -1 
a (Å) 7.4833(2) 12.3517(16) 7.9356(9) 
b (Å) 8.1520(2) 8.3507(11) 10.3848(12) 
c (Å) 16.1344(4) 18.174(2) 13.1949(15) 
α (o) 98.002(1) 90 108.741(3) 
β (o) 91.532(1) 98.788(4) 93.495(3) 
γ (o) 102.448(1) 90 109.913(3) 
V (Å3) 950.13(4) 1852.56 950.27(19) 
Z 2 4 2 
Pcalc (gcm
-3) 1.366 1.436 1.403 
R-factor (%) 3.6 7.5 4.09 
µ (mm-1) 0.206 0.209 0.206 
θ (max)  27.484 27.545 27.501 
Nref 4363 4237 4370 
Npar 255 255 256 
Goodness-of-fit 
(GOF) 
1.035 1.062 1.041 
Crystal shape* Plate Plate Plate 
CCDC number 1916774 1916775 1916776 
*Refer to Figure 7.5 
 
7.2.6 Hirshfeld Surface Analysis and Interaction Energy Calculations 
The Hirshfeld plots and the 2D fingerprint plots are given in Figures A.39-A.44, Appendix. The 
relative contribution of the possible intermolecular interactions for each unique molecule in the 
crystal structure is plotted in Figure 7.6. Different shapes of the surfaces for the co-crystals as 
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compared to their components’ illustrate different packing motif and intermolecular 
arrangement. The major bonding contribution in all structures is H-H type bonding signifying 
the importance of the contribution of van der Waals interactions. Even though the particular 
hydrogen bonds are strong, their contribution to the overall crystal structural bonding is small 
as compared to the total van der Waals bonding.  
 
Figure 7.6. The relative contribution of intermolecular interactions for each unique molecule in 
the structures for the three co-crystals and their pure components. 
The overall energy profiles for all the crystal structures can be seen in Table A1-8 (Appendix). 
The total energy values and the contributions from the various components is summarized in 
Table 7.4. In single-component crystal structures of SMT and SMR, dispersion energy is the 
major contributor for total interaction energies. This is also applicable to the multicomponent 
systems of SMR-AA and SMR-SAL co-crystals; however, in SMT-NIC co-crystal electrostatic 
interaction provides major contribution. In all cases, the interaction energy of the co-crystals is 
more negative as compared to the pure components, in line with the stability of the co-crystals 
over the pure components. The co-crystal interaction energies are higher as compared to the 
summation of the pure components in SMT-NIC and SMR-AA cases except in SMR-SAL, 
where it is only slightly lower by 6.2 kJ/mol or 1.34 %. It is noteworthy that the interaction 
energy of SMR is much higher than of SMT, by ~ 70 kJ/mol, explaining the higher stability of 
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SMR over SMT, and hence its lower reactivity towards co-crystal formation as supported by the 
arguments above. 














SMT -123.6 -41.7 -216.2 195.1 -229.5 
SMR -186.2 -59.7 -245 246.4 -301.7 
NIC -97.2 -26.4 -115.5 140.1 -136 
AA -138 -32.6 -108.1 205.3 -137.2 
SAL -124.7 -29.6 -104 139 -158.6 
SMT-NIC -440.1 -165.5 -428.8 518.8 -640.6 
SMR-AA -321.7 -98 -427.6 485 -485.7 
SMR-SAL -300.3 -92.1 -388.8 437.7 -454.1 
 
7.2.7 Thermal Analysis 
The TGA and DSC thermograms are given in Figure 7.7. In none of the systems, there is a mass 
loss before melting suggesting the absence of any unbound water or absorbed solvents. The DSC 
thermograms for all the samples showed a single peak corresponding to their melting. The 
extrapolated onset melting temperatures (Tm, onset) and associated melting enthalpies (∆fusH (Tm)) 
for the pure components and co-crystals are given in Table 7.5, from which the corresponding 
melting entropies (∆fusS (Tm) were determined. Note that the table gives the co-crystal data as 
per mole 1:1 API-coformer entity, explaining the much higher enthalpy and entropy values. The 
co-crystal enthalpy and entropy values for SMR-AA and SMR-SAL are lower than the sum of 
the pure component values. The value for the SMT-NIC co-crystal is only slightly higher than 
the sum of the pure component values. The melting temperatures of the co-crystals are well 
defined and placed between the melting points of the pure compounds. 
The melting temperatures of the new co-crystals are close, the order being, SMR-SAL > SMT-




Figure 7.7. TGA (left) and DSC (right) thermograms of the co-crystals and their components; 
(a)  (i) SMR, (ii) SMR-SAL co-crystal, (iii) SAL, (b) (i) SMR, (ii) SMR-AA co-crystal, (iii) 





Table 7.5. Thermodynamic parameters for APIs (SMT, SMR), coformers (NIC, AA, SAL) 
and the three new co-crystals (SMT-NIC, SMR-AA, SMR-SAL). 
Compound 
Melting temperature 
(Tm,  onset, 
oC) 
Enthalpy of melting 
(∆fusH (Tm), kJ/mol)* 
Entropy of melting 
(∆fusS (Tm), kJ/K.mol) 
SMT 198.38 36.2 0.0767 
SMR 239.13 37.8 0.0736 
NIC 127.19 24.0 0.0599 
AA 144.56 21.9 0.0523 
SAL 139.36 28.7 0.0696 
SMT-NIC 167.59 61.5 0.1395 
SMR-AA 162.55 41.9 0.0962 
SMR-SAL 169.19 56.1 0.1268 
*1 mol for 1:1 co-crystal = 1 mol of API + 1 mol of coformer 
7.2.8 Raman and FT-IR Spectroscopy  
Figure 7.8 depicts the Raman spectra for the new co-crystals in comparison with the pure 
components. Significant differences in the spectra can be observed. The spectra are complex 
because the molecules are asymmetric and unique because the environment for atoms in the 
single components and the co-crystals is different. The carbonyl (C=O) stretch that appears at 
1677, 1622 and 1625 cm-1 in NIC, AA and SAL, respectively, undergoes a shift in the co-crystals 
to 1643, 1658 and 1621 cm-1. In the NIC, AA and SAL solid structures, two molecules interact 
to form (carbonyl) C=O---N-H (amine/amide) type interactions. In SMT-NIC co-crystal, C=O 
interacts with N-H of the SMT pyrimidine ring, in the SMR-AA co-crystal with N-H of the SMR 
sulfonamide group, and in the SMR-SAL co-crystal with the N-H of the second SAL molecule. 
A change in the chemical environment changes the C=O bond length from 1.217 (NIC) to 1.240 
Å (SMT-NIC); from 1.268 (AA) to 1.226 Å (SMR-AA); and from 1.222 (SAL) to 1.254 (SMR-
SAL), which is reflected in the appearance of the C=O peak at different wavenumbers.   
Figure 7.9 presents the FT-IR spectra of the new co-crystals and their components. The co-
crystal spectra are slightly different from the starting components. The co-crystal spectra depict 
many bands that are present in both API and coformer, corresponding to the structures of API 
and coformer. Presence of additional unique bands and shift of peaks to higher or lower 
wavenumbers depict the intermolecular hydrogen bonds present in the co-crystal. From the 
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zoom-in FT-IR spectra, the shift in carbonyl peaks (C=O) can be seen between 1600-1800 cm-
1. NIC, AA and SAL have C=O stretch at 1678 cm-1, 1664 cm-1 and 1669 cm-1, respectively, 
while in the  co-crystals  it is observed at 1659 cm-1, 1668 cm-1 and 1664 cm-1, complementing 
Raman analysis. The three N-H bands in pure SMT at 3437, 3344 and 3225 cm-1 shift to 3423, 
3329 and 3210 cm-1 respectively in the SMT-NIC co-crystal. These bands arise from the 
pyrimidine and amino group stretches. In pure SMT, two intermolecular hydrogen bonds 
(sulfonamide) N–H---O (sulfonamide) and (amino) N–H---N (pyrimidine nitrogen) exist, 
whereas in the co-crystal, the SMT amino group acts as a hydrogen bond donor to the 
sulfonamide oxygen and the pyrimidine nitrogen, and the sulfonamide N-H interacts with the 
coformer amide group to form a ring moiety. These interactions are responsible for the N-H 
frequency shifts. Similar shifts are observed in SMR-AA and SMR-SAL co-crystals. The N-H 
stretch in NIC shows a shift from 3355 to 3376 cm-1 in the SMT-NIC co-crystal. The O-H and 












Figure 7.9. FT-IR spectra of the new co-crystals in comparison with their components. 
104 
 
7.2.9 Equilibrium and Stability 
The concentration of SMT and SMR obtained after equilibrating with the pure solids and the 
three co-crystals are given in Table 7.7, which match well with solubility data in the literature.20, 
21 Clearly, the new co-crystals give a higher API concentration as compared to that of pure solid 
API. The equilibrium concentration of API when co-crystal material and water is equilibrated, 
is for all three new co-crystals higher than the solubility of the pure API, by 25.5 %, 22.3 % 
and 15.9 %, for SMT-NIC, SMR-AA and SMR-SAL, respectively. This concentration increase 
follows the order of solubility of the pure solid coformers.22-24 This suggests that selecting high 
solubility coformers could possibly lead to co-crystals that produce higher API concentrations 
in solutions.                                           
Table 7.7. Comparison of aqueous concentration of SMT or SMR in equilibrium with pure API 
and co-crystals 
Compound 
API concentration  Solid in equilibrium 
with saturated solution g/L mol/L (103)* 
SMT 0.4478 1.60 SMT 
SMT-NIC 0.5620 2.02 SMT 
SMR 0.2477 0.93 SMR 
SMR-AA 0.3029 1.14 SMR-AA 
SMR-SAL 0.2872 1.08 SMR-SAL + SMR 
*1 mol co-crystal = 1 mol API + 1 mol coformer  
 
In the stability work, no change in the dry solid form was observed for any of the three new co-
crystals after 9 weeks under accelerated stability tests (40 oC, RH 75%) as observed by PXRD 
analysis. The solid co-crystals did not change any form even after 6 months when stored in a 
lab drawer under ambient conditions as seen in the co-crystal PXRD patterns (See Figure A.33-
A.35, Appendix). 
The solid forms added for both SMT and SMR solubility experiments were form I each. There 
was no form change for both solid SMT and SMR on dissolution in water i.e. form I, same as 
the added form was obtained in both cases. However, concerning the co-crystals, only SMR-
AA co-crystal stayed as pure co-crystal upon partial dissolution in water, indicating congruent 
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dissolution; however, SMT-NIC and SMR-SAL both changed form to the solid API indicating 
incongruent dissolution in water at 25 oC as is illustrated by the schematic ternary phase 
diagrams in Figure 2.4. Considering the dissolution of co-crystal along the 1:1 stoichiometric 
line, starting from the solvent vertex moving towards point 1:1 co-crystal point, C on the solid 
axis, for congruent dissolution (Figure 2.4) the co-crystal will be the equilibrium solid phase, 
irrespective of where the dissolution process is stopped. However, for incongruent dissolution 
(Figure 2.4b), depending on the amount of solid phase added, either pure API (lower amount 
of solid phase) or a mixture of API and co-crystal (higher amount of solid phase) can be the 
equilibrium solid material, as the stoichiometric line crosses into region 2 and 4, where the 
stable solid phases are API and a mixture of API and co-crystal respectively. 
7.3 Conclusions 
In this study, three new co-crystals: sulfamethazine-nicotinamide, sulfamerazine-anthranilic 
acid, sulfamerazine-salicylamide have been found and efficiently manufactured by microwave 
irradiation slurry conversion co-crystallization. In slurry conversion crystallization at the same 
elevated temperature, microwaves as the source of heating are found to increase the rate by 
which co-crystals are formed, compared to normal heating. The alternating electromagnetic 
field appears to promote the solid phase transformation beyond the effect of just the temperature 
increase. It is shown that the microwave-assisted slurry conversion for co-crystal manufacturing 
can be scaled up with the same outcome from 0.2 g to 20 g. Characterization by various 
analytical techniques confirmed the formation of new co-crystals. Thermal analysis shows the 
melting point of the co-crystals to be between those of the corresponding pure components. The 
spectroscopic studies showed peak shifts in spectra of co-crystals as compared to those of pure 
components, showing different bonding patterns. The co-crystals show improved dissolution 
properties and a correlation with the solubility of coformers. By Hirshfeld surface analysis and 
interaction energy calculations, the difference in stability, reactivity and rate of formation of 
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Chapter 8. General Conclusions and Future 
Outlook 
The isothermal slurry conversion co-crystallization seems to be a promising robust technique 
for co-crystal manufacture, with potential application in commercial synthesis. Production of 
the pure product, of course, requires the dosage of starting material in specific ratios such that 
the overall composition stays in the region of the ternary phase diagram where co-crystal is the 
stable phase. The co-crystal dissolution behavior and the solvent choice were no obstacle to co-
crystal synthesis by slurry conversion, as demonstrated by two co-crystal systems in different 
solvents. A large region in the phase diagram where co-crystal is stable, aids the robustness of 
the crystallization process. The efficiency of this process can further be enhanced by designing 
a continuous manufacture crystallization method. As long as starting material are added as per 
the phase diagram where co-crystal is the stable phase and the liquid composition is along the 
co-crystal solubility curve, the pure product could be continuously isolated and replaced by 
stoichiometric amounts of solids (See Figure 8.1). 
The microwave-assisted slurry conversion proved to enhance the rate of co-crystal formation 
as compared to simple heating to the same temperature and all the other conditions the same. 
For three different co-crystals, the process outcome is the same at three different manufacturing 
scales. We learnt that the favorable effect of the alternating electromagnetic field to promote 
co-crystal formation went beyond simple heating. This is probably due to the ability of 
microwaves to influence on the molecular structuring in solution, but the detailed mechanisms 
are not fully understood and need further investigation. Nonetheless, this finding motivates an 
increased interest for industrial co-crystal manufacture and perhaps in particular for continuous 
manufacturing systems. Despite the dramatic reaction time reduction, the problems and 
challenges associated with microwave reactions must be taken in consideration when 
developing a process. These include limited penetration depth for large scales, degradation of 
reactants or products and safety concerns like pressure build up in sealed reaction vessels. The 
possible solutions to these issues include rapid agitation, application of temperature control 
with sensors or probes and construction of pressure release outlets or other venting mechanisms 
for reactions in closed vessels. Development of continuous flow systems would be particularly 
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useful to solve the problem of penetration depth. Hence, further advancement in this field can 
promote microwave-assisted conversion for commercial co-crystal manufacture.   
The two structurally similar drugs, SMT and SMR showed a difference in reactivity and rate of 
co-crystal formation via microwave assisted synthesis. The stable crystal structure of SMR, 
higher melting temperature and higher interaction energy supported this observation. The 
equilibrium concentration of the API in the solution when co-crystals were added to water was 
higher than the solubility of pure API. The increase was 25.5 %, 23.3 % and 15.9 % for SMT-
NIC, SMR-AA and SMR-SAL co-crystals respectively, in order of the solubility of coformers. 
This suggested that selection of high solubility coformers could produce co-crystals that 
produce high API concentration in equilibrium solution. 
 




The appearance and symmetry of the ternary phase diagram were found to be strongly 
dependent on the choice of solvent for both 1:1 sulfamethazine-salicylic acid and 1:1 
sulfamethazine-3-methylsalicylic acid systems. Temperature did not show a significant effect 
over the 20 oC temperature range studied. 
Using solubility data, the Gibbs energy of co-crystal formation from pure, solid components 
was found to be negative for both systems, signifying the stability of the co-crystal over its pure 
components. The co-crystal formation was an endothermic process in both cases. For SMT-SA, 
the entropy change was found to be positive, which seemed to be driving the co-crystal 
formation. A favorable entropy increase has been correlated to volume expansion. This finding 
challenges the existing computational approaches to predict co-crystal formation based on 
relative lattice energies that ignore the entropy contribution. 
It was seen that the solubility ratio between the two co-crystal components could not predict 
with absolute confidence the dissolution behavior of a co-crystal. The size of the region where 
the co-crystal is the stable solid phase is however found to be inversely proportional to the 
solubility ratio of coformer and API. 
In the process, three new solvates for SMT with the solvents dimethylsulfoxide, N,N-
dimethylacetamide, and N,N-dimethylformamide were identified and thoroughly characterized 
by various analytical techniques. Desolvation of solvates produced pure crystalline SMT, not 










Figure A.1. Full (top) and zoom-in view (bottom) of ternary phase diagram of SMT-SA co-





Figure A.2. Full (top) and zoom-in view (bottom) of ternary phase diagram of SMT-SA co-





Figure A.4.3. Ternary phase diagram of SMT-SA co-crystal system in methanol at 30°C. The 






Figure A.4. Full (top) and zoom-in view (bottom) of ternary phase diagram of SMT-SA co-





Figure A.5. Full (top) and zoom-in view (bottom) of ternary phase diagram of SMT-SA co-





Figure A.6. Ternary phase diagram of SMT-SA co-crystal system in acetonitrile at 30°C. The 







Figure A.7. Ternary phase diagram of SMT-SA co-crystal system in 7:3 (v/v) DMSO-methanol 






Figure A.8. Ternary phase diagram of SMT-SA co-crystal system in 7:3 (v/v) DMSO-methanol 




Figure A.9. A zoom-in view of the ternary phase diagram of SMT-SA co-crystal system in 
acetonitrile depicting the solubility points and invariant points at 10 (red), 20 (blue) and 30oC 
(green) showing the effect of temperature. 
 
Figure A.10. A zoom-in view of the ternary phase diagram of SMT-SA co-crystal system in 
methanol depicting the solubility points and invariant points at 10 (red), 20 (blue) and 30oC 




Figure A.11. A zoom-in view of the ternary phase diagram of SMT-SA co-crystal system in 
7:3 (v/v) DMSO-methanol mixture depicting the solubility points and invariant points at 20 
(red), 30 (blue) and 40oC (green) showing the effect of temperature. 
 
Figure A.12. PXRD patterns of the pure SMT, 1:1 SMT-SA co-crystal and the invariant points 




Figure A.13. DSC thermograms of the invariant points at 10 (red), 20 (blue) and 30oC (green) 
in methanol where SMT and co-crystal co-exist. 
 
Figure A.14. PXRD patterns of the pure SA, 1:1 SMT-SA co-crystal and the invariant points 
at 10 (red), 20 (blue) and 30oC (green) in methanol where SA and co-crystal co-exist. 
 
Figure A.15. DSC thermograms of the invariant points at 10 (red), 20 (blue) and 30oC (green) 





Figure A.16. PXRD patterns of the pure SMT, 1:1 SMT-SA co-crystal and the invariant points 
at 10 (red), 20 (blue) and 30oC (green) in ACETONITRILE where SMT and co-crystal co-exist. 
 
 
Figure A.17. DSC thermograms of the invariant points at 10 (red), 20 (blue) and 30oC (green) 









Figure A.18. PXRD patterns of the pure SA, 1:1 SMT-SA co-crystal and the invariant points 
at 10 (red), 20 (blue) and 30oC (green) in acetonitrile where SA and co-crystal co-exist. 
 
 
Figure A.19. DSC thermograms of the invariant points at 10 (red), 20 (blue) and 30oC (green) 






Figure A.20. PXRD patterns of the pure SMT, 1:1 SMT-SA co-crystal and the invariant points 
at 10 (red), 20 (blue) and 30oC (green) in 7:3 (v/v) DMSO-methanol mixture where SMT and 
co-crystal co-exist. 
 
Figure A.21. DSC thermograms of the invariant points at 10 (red), 20 (blue) and 30oC (green) 







Figure A.22. PXRD patterns of the pure SA, 1:1 SMT-SA co-crystal and the invariant points 
at 10 (red), 20 (blue) and 30oC (green) in 7:3 (v/v) DMSO-methanol mixture where SA and co-
crystal co-exist. 
 
Figure A.23. DSC thermograms of the invariant points at 10 (red), 20 (blue) and 30oC (green) 






Figure A.24. PXRD patterns of sulfamethazine (SMT), salicylic acid (SA), co-crystal obtained 




Figure A.25. PXRD patterns of sulfamethazine (SMT), anthranilic acid (AA), co-crystal 







Figure A.26. PXRD patterns of sulfamethazine (SMT), benzamide (BEN), co-crystal obtained 





Figure A.27. PXRD patterns of sulfamethazine (SMT), aspirin (ASP), co-crystal obtained from 






Figure A.28. PXRD patterns of sulfamethazine (SMT), salicylamide (SAL) and solid from 




Figure A.29. PXRD patterns of sulfamerazine (SMR), salicylic acid (SA) and solid from 






Figure A.30. PXRD patterns of sulfamerazine (SMR), nicotinamide (NIC) and solid from 




Figure A.31. PXRD patterns of sulfamerazine (SMR), benzamide (BEN) and solid from 






Figure A.32. PXRD patterns of sulfamerazine (SMR), aspirin (ASP) and solid from 






Figure A.33. PXRD patterns of SMR-AA co-crystal after 6 months (bench), after 1 day, and 






Figure A.34. PXRD patterns of SMR-SAL co-crystal after 6 months (bench), after 1 day, and 





Figure A.35. PXRD patterns of SMT-NIC co-crystal after 6 months (bench), after 1 day, and 







Figure A.36.  PXRD patterns of the three co-crystals after 10 times and 100 times scale-up. 
 
Table A.1. Hydrogen bond parameters for SMT-NIC co-crystal in (Å, o).  
D-H--A D-H H--A D--A Å 
N2B-H2B1--N7A          0.88 2.22 3.058(4) 159  
N2B-H2B2--O17A 0.88 2.24 3.073(4) 157 
N3A-H3A--O1B 0.88 1.83 2.699(4) 168 
N15A-H15A--O16A         0.88 2.12 2.950(4) 157 
N15A-H15B--N6B          0.88 2.43 3.105(4) 133 
C14A-H14A--O16A         0.95 2.46 2.865(4) 105 
                        . 
Table A.2. Hydrogen bond parameters for SMR-SAL co-crystal in (Å, o).  
D-H--A D-H H--A D--A Å 
N8B-H8B1--O10B          0.88 2.10 2.9153(19)      154   
N8B-H8B2--O16A 0.88 2.25 3.0506(16)      151 
N7A-H7A--N3A 0.88 2.10 2.8989(18)      151 
O7B-H7B--O10B 0.84 1.77 2.5139(17) 147 
N15A-H15A--O7B          0.88 2.17 3.0214(19)      162 
N15A-H15B--O16A                 0.88 2.28 3.0308(18)      143 
N15A-H15B--N1A 0.88 2.52 3.2183(19)      137 
C4A-H4A--O17A 0.95 2.52 3.2444(19 133 
134 
 
C10A-H10A--O16A         0.95 2.58 2.9397(19) 102 
 
Table A.3. Hydrogen bond parameters for SMR-AA co-crystal in (Å, o).  
D-H--A D-H H--A D--A Å 
O1B-H1B--N1A          0.82 2.00 2.813(2)      174    
N7A-H7A--O2B 0.86 1.98 2.723(2) 144 
N10B-H10B--O17A 0.86 2.29 3.030(2) 144 
N10B-H10C--O2B          0.86 2.04 2.664(3) 129 
N15A-H15A-- N3A          0.86 2.45 3.286(2) 163 
C8B-H8B-- O16A         0.93 2.56 3.340(3) 142 















Figure A.39.  Hirshfeld surface plots of SMT form I (a), NIC (b), SMT molecule in SMT-NIC 






Figure A.40.  Hirshfeld surface plots of SMR form I (a), AA (b), SMR molecule in SMR-AA 






Figure A.41.  Hirshfeld surface plots of SAL (a), SMR molecule in SMR-SAL co-crystal (b) 





Figure A.42.  2-D finger plots of SMT form I (a), NIC (b), SMT molecule in SMT-NIC co-





Figure A.43.  Hirshfeld surface plots of SMR molecule 1 (a), SMR molecule 2 (b) AA (c), 





Figure A.44.  2-D fingerprint plots of SAL (a), SMR molecule in SMR-SAL co-crystal (b) AA 




Information for Tables A.4- A.11: 
The interaction energies are in kJ/mol. ‘R’ is the distance between molecular centroids in Å. 
Total energies are the sum of four energy components, scaled appropriately as per the scale 
factors: 
Energy Model k_ele k_pol k_disp k_rep 
CE-B3LYP ... B3LYP/6-31G(d,p) electron densities 1.057 0.740 0.871 0.618 
 
Equation A.1.  𝐸𝑡𝑜𝑡 = 𝑘𝑒𝑙𝑒𝐸𝑒𝑙𝑒 + 𝑘𝑝𝑜𝑙𝐸𝑝𝑜𝑙 + 𝑘𝑑𝑖𝑠𝐸𝑑𝑖𝑠 + 𝑘𝑟𝑒𝑝𝐸𝑟𝑒𝑝 
 
Table A.4. Interaction energy profile for SMT. 
Symop R Electron Density E_ele E_pol E_dis E_rep E_tot 
x, y, z 7.43 B3LYP/6-31G(d,p) 0.8 -2.5 -7.6 1.8 -6.6 
-x+1/2, y+1/2, -z 12.41 B3LYP/6-31G(d,p) 0.2 -0.1 -2.1 0.1 -1.7 
x, y, z 9.32 B3LYP/6-31G(d,p) -9.2 -4.3 -21.7 18.1 -20.7 
x+1/2, -y+1/2, z 10.29 B3LYP/6-31G(d,p) -7.6 -2.9 -8.3 4.0 -14.9 
x+1/2, -y+1/2, z 11.31 B3LYP/6-31G(d,p) 2.3 -0.4 -3.7 0.4 -0.9 
x+1/2, -y+1/2, z 5.47 B3LYP/6-31G(d,p) -19.1 -9.2 -47.9 49.7 -38.1 
-x, -y, -z 10.24 B3LYP/6-31G(d,p) 1.7 -0.1 -2.0 0.0 0.1 
-x, -y, -z 6.19 B3LYP/6-31G(d,p) -33.6 -8.3 -45.6 44.3 -54.0 
-x, -y, -z 7.38 B3LYP/6-31G(d,p) -33.2 -9.1 -58.0 53.7 -59.1 
-x+1/2, y+1/2, -z 9.63 B3LYP/6-31G(d,p) -24.7 -4.6 -14.7 21.2 -29.3 
-x, -y, -z 10.52 B3LYP/6-31G(d,p) -1.2 -0.2 -4.6 1.8 -4.3 
 
Table A.5. Interaction energy profile for NIC. 
Symop R Electron Density E_ele E_pol E_dis E_rep E_tot 
x, y, z 3.88 B3LYP/6-31G(d,p) 5.6 -1.3 -29.6 15.8 -11.0 
-x, -y, -z 7.15 B3LYP/6-31G(d,p) -3.9 -0.6 -12.0 11.2 -8.1 
-x, -y, -z 8.20 B3LYP/6-31G(d,p) -9.8 -1.6 -10.2 12.7 -12.6 
x, -y+1/2, z+1/2 6.71 B3LYP/6-31G(d,p) -37.7 -9.0 -12.5 35.4 -35.5 
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x, -y+1/2, z+1/2 5.95 B3LYP/6-31G(d,p) -36.1 -8.2 -12.7 31.9 -35.6 
-x, -y, -z 5.59 B3LYP/6-31G(d,p) -12.0 -2.5 -17.7 16.3 -19.8 
-x, y+1/2, -z+1/2 7.93 B3LYP/6-31G(d,p) 2.7 -1.0 -6.2 2.8 -1.5 
-x, -y, -z 5.88 B3LYP/6-31G(d,p) -7.5 -1.7 -12.4 13.9 -11.3 
-x, y+1/2, -z+1/2 8.46 B3LYP/6-31G(d,p) 1.5 -0.5 -2.2 0.1 -0.6 
 
Table A.6. Interaction energy profile for SMT-NIC co-crystal 
Symop R Electron Density E_ele E_pol E_dis E_rep E_tot 
- 4.31 B3LYP/6-31G(d,p) 0.1 -4.4 -41.6 19.0 -27.6 
- 7.20 B3LYP/6-31G(d,p) -112.1 -27.6 -20.2 105.4 -91.4 
- 6.23 B3LYP/6-31G(d,p) -33.2 -11.6 -25.1 34.1 -44.5 
- 6.93 B3LYP/6-31G(d,p) -0.1 -0.5 -3.6 0.1 -3.6 
- 11.94 B3LYP/6-31G(d,p) 5.2 -0.5 -1.1 0.0 4.2 
-x, -y, -z 5.23 B3LYP/6-31G(d,p) -1.9 -1.8 -16.2 7.1 -13.1 
- 5.96 B3LYP/6-31G(d,p) -7.7 -7.4 -31.5 15.1 -31.7 
- 7.78 B3LYP/6-31G(d,p) -18.7 -4.4 -21.7 31.5 -22.4 
-x, y+1/2, -z+1/2 9.96 B3LYP/6-31G(d,p) -4.4 -2.5 -10.7 6.7 -11.7 
-x, -y, -z 9.71 B3LYP/6-31G(d,p) 5.3 -0.7 -7.9 2.8 -0.0 
- 7.78 B3LYP/6-31G(d,p) -18.7 -4.4 -21.7 31.5 -22.4 
-x, -y, -z 6.73 B3LYP/6-31G(d,p) -14.4 -5.3 -28.6 14.1 -35.4 
x, -y+1/2, z+1/2 9.55 B3LYP/6-31G(d,p) -8.4 -4.1 -21.0 18.3 -18.9 
x, y, z 8.35 B3LYP/6-31G(d,p) -20.9 -10.6 -10.7 26.2 -23.1 
- 6.93 B3LYP/6-31G(d,p) -0.1 -0.5 -3.6 0.1 -3.6 
- 4.31 B3LYP/6-31G(d,p) 0.1 -4.4 -41.6 19.0 -27.6 
-x, -y, -z 7.56 B3LYP/6-31G(d,p) -42.3 -15.5 -30.9 22.6 -69.1 
x, -y+1/2, z+1/2 10.58 B3LYP/6-31G(d,p) -28.3 -7.2 -8.8 9.8 -36.9 
-x, y+1/2, -z+1/2 8.76 B3LYP/6-31G(d,p) 8.2 -5.0 -4.4 0.8 1.6 
- 7.20 B3LYP/6-31G(d,p) -112.1 -27.6 -20.2 105.4 -91.4 
- 6.23 B3LYP/6-31G(d,p) -33.2 -11.6 -25.1 34.1 -44.5 
- 11.94 B3LYP/6-31G(d,p) 5.2 -0.5 -1.1 0.0 4.2 
- 5.96 B3LYP/6-31G(d,p) -7.7 -7.4 -31.5 15.1 -31.7 
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Table A.7. Interaction energy profile for SMR. 
- 6.72 B3LYP/6-31G(d,p) 12.4 -5.6 -29.8 17.2 -6.3 
x+1/2, y, -z+1/2 7.72 B3LYP/6-31G(d,p) -15.1 -4.3 -16.6 12.1 -26.0 
x+1/2, y, -z+1/2 9.10 B3LYP/6-31G(d,p) -0.6 -1.4 -9.8 5.2 -7.1 
- 6.71 B3LYP/6-31G(d,p) -74.9 -13.3 -31.4 91.8 -59.6 
- 7.24 B3LYP/6-31G(d,p) -8.2 -1.7 -30.1 14.1 -27.4 
- 10.57 B3LYP/6-31G(d,p) -14.0 -2.5 -4.2 1.4 -19.4 
- 7.57 B3LYP/6-31G(d,p) -14.7 -5.4 -23.5 16.7 -29.6 
x, y, z 8.20 B3LYP/6-31G(d,p) -25.8 -9.5 -21.6 27.5 -36.1 
- 7.29 B3LYP/6-31G(d,p) -10.1 -1.9 -33.3 19.8 -28.7 
- 12.96 B3LYP/6-31G(d,p) 3.8 -0.7 -1.6 0.0 2.1 
x, y, z 8.20 B3LYP/6-31G(d,p) -26.1 -8.2 -18.2 25.6 -33.6 
x+1/2, y, -z+1/2 7.69 B3LYP/6-31G(d,p) -12.2 -3.9 -15.8 11.0 -22.8 
x+1/2, y, -z+1/2 9.15 B3LYP/6-31G(d,p) -0.7 -1.3 -9.1 4.0 -7.2 
 
Table A.8. Interaction energy profile for AA. 
N Symop R Electron Density E_ele E_pol E_dis E_rep E_tot 
1 -x, -y, -z 3.56 B3LYP/6-31G(d,p) -1.4 -1.0 -38.7 19.9 -23.6 
1 -x, -y, -z 7.18 B3LYP/6-31G(d,p) -117.6 -26.6 -13.4 148.7 -63.8 
2 -x, y+1/2, -z+1/2 7.29 B3LYP/6-31G(d,p) 2.7 -0.6 -5.4 1.4 -1.4 
1 x, y, z 7.16 B3LYP/6-31G(d,p) -3.2 -0.4 -6.3 1.0 -8.5 
1 x, -y+1/2, z+1/2 6.78 B3LYP/6-31G(d,p) -13.1 -2.9 -11.6 13.6 -17.7 
0 -x+1/2, -y, z+1/2 5.78 B3LYP/6-31G(d,p) -3.5 -0.6 -17.6 10.9 -12.7 
0 -x+1/2, y+1/2, z 7.37 B3LYP/6-31G(d,p) 0.2 -0.3 -4.7 1.2 -3.3 
1 x, -y+1/2, z+1/2 6.87 B3LYP/6-31G(d,p) -2.1 -0.2 -10.4 8.6 -6.2 
 
Table A.9. Interaction energy profile for SMR-AA. 
Symop R Electron Density E_ele E_pol E_dis E_rep E_tot 
- 7.02 B3LYP/6-31G(d,p) -16.7 -5.6 -19.0 24.0 -23.6 
- 10.91 B3LYP/6-31G(d,p) 0.4 -0.3 -3.5 0.7 -2.5 
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-x, -y, -z 7.83 B3LYP/6-31G(d,p) -3.0 -0.5 -4.1 0.4 -6.9 
- 5.97 B3LYP/6-31G(d,p) -8.5 -3.9 -35.0 24.9 -26.9 
- 6.91 B3LYP/6-31G(d,p) -2.0 -0.2 -3.1 0.0 -5.0 
- 12.16 B3LYP/6-31G(d,p) 0.2 -0.3 -1.4 0.0 -1.1 
-x, -y, -z 5.31 B3LYP/6-31G(d,p) -4.9 -0.7 -16.1 5.8 -16.2 
- 9.56 B3LYP/6-31G(d,p) 0.4 -0.1 -1.3 0.0 -0.8 
-x, -y, -z 8.71 B3LYP/6-31G(d,p) -1.2 -0.1 -5.1 2.1 -4.5 
- 6.61 B3LYP/6-31G(d,p) -86.7 -19.7 -21.1 111.6 -55.7 
- 4.58 B3LYP/6-31G(d,p) -6.5 -1.5 -40.3 20.6 -30.4 
- 8.65 B3LYP/6-31G(d,p) -3.5 -0.7 -9.8 7.0 -8.4 
- 9.53 B3LYP/6-31G(d,p) 1.4 -0.5 -2.9 0.1 -1.4 
-x, -y, -z 8.51 B3LYP/6-31G(d,p) -1.4 -0.1 -1.4 0.0 -2.8 
x, y, z 7.94 B3LYP/6-31G(d,p) -13.7 -5.5 -14.0 13.0 -22.7 
-x, -y, -z 7.12 B3LYP/6-31G(d,p) -1.2 -6.1 -11.1 10.5 -8.9 
- 8.65 B3LYP/6-31G(d,p) -3.5 -0.7 -9.8 7.0 -8.4 
x, y, z 10.71 B3LYP/6-31G(d,p) -4.7 -1.0 -1.9 0.1 -7.2 
- 7.02 B3LYP/6-31G(d,p) -16.7 -5.6 -19.0 24.0 -23.6 
- 5.97 B3LYP/6-31G(d,p) -8.5 -3.9 -35.0 24.9 -26.9 
-x, -y, -z 6.79 B3LYP/6-31G(d,p) -42.4 -14.0 -57.2 56.0 -70.4 
x, y, z 10.38 B3LYP/6-31G(d,p) 0.7 -1.5 -14.8 9.9 -7.2 
-x, -y, -z 9.16 B3LYP/6-31G(d,p) -4.2 -0.5 -3.3 0.3 -7.5 
- 9.56 B3LYP/6-31G(d,p) 0.4 -0.1 -1.3 0.0 -0.8 
-x, -y, -z 7.55 B3LYP/6-31G(d,p) -2.7 -2.3 -20.9 8.5 -17.5 
- 6.61 B3LYP/6-31G(d,p) -86.7 -19.7 -21.1 111.6 -55.7 
- 4.58 B3LYP/6-31G(d,p) -6.5 -1.5 -40.3 20.6 -30.4 
-x, -y, -z 14.91 B3LYP/6-31G(d,p) -0.0 -0.1 -2.9 0.6 -2.3 
- 10.91 B3LYP/6-31G(d,p) 0.4 -0.3 -3.5 0.7 -2.5 
- 12.16 B3LYP/6-31G(d,p) 0.2 -0.3 -1.4 0.0 -1.1 
- 9.53 B3LYP/6-31G(d,p) 1.4 -0.5 -2.9 0.1 -1.4 




Table A.10. Interaction energy profile for SAL. 
Symop R Electron Density E_ele E_pol E_dis E_rep E_tot 
x+1/2, -y+1/2, z 7.95 B3LYP/6-31G(d,p) 0.1 -0.3 -3.5 0.7 -2.7 
-x, -y, -z 10.10 B3LYP/6-31G(d,p) -0.1 -0.1 -1.4 0.1 -1.3 
x+1/2, -y+1/2, z 6.46 B3LYP/6-31G(d,p) -33.8 -7.9 -13.1 33.8 -32.2 
-x, -y, -z 7.47 B3LYP/6-31G(d,p) -3.5 -0.3 -8.4 3.7 -9.0 
-x, y, -z+1/2 6.20 B3LYP/6-31G(d,p) 4.4 -0.9 -5.9 0.7 -0.7 
x, y, z 4.98 B3LYP/6-31G(d,p) 3.5 -1.6 -24.5 12.9 -10.8 
x+1/2, -y+1/2, z 8.36 B3LYP/6-31G(d,p) -3.0 -0.4 -1.6 0.0 -4.8 
-x+1/2, y+1/2, -z 6.63 B3LYP/6-31G(d,p) -3.1 -0.5 -11.4 6.9 -9.4 
-x+1/2, -y+1/2, -z+1/2 5.36 B3LYP/6-31G(d,p) -17.0 -2.4 -22.0 13.8 -30.4 
-x+1/2, -y+1/2, -z+1/2 7.54 B3LYP/6-31G(d,p) -72.2 -15.2 -12.2 66.4 -57.3 
 
Table A.11. Interaction energy profile for SMR-SAL. 
Symop R Electron Density E_ele E_pol E_dis E_rep E_tot 
- 6.95 B3LYP/6-31G(d,p) -27.0 -7.4 -13.2 19.9 -33.3 
-x, -y, -z 3.52 B3LYP/6-31G(d,p) -7.9 -2.1 -40.4 23.7 -30.4 
-x, -y, -z 7.43 B3LYP/6-31G(d,p) -60.6 -12.4 -11.9 54.7 -49.9 
- 7.21 B3LYP/6-31G(d,p) 3.6 -1.9 -11.6 6.3 -3.8 
- 7.65 B3LYP/6-31G(d,p) 2.2 -2.6 -6.1 3.5 -2.8 
- 8.09 B3LYP/6-31G(d,p) 0.7 -1.4 -15.4 12.3 -6.1 
x, y, z 8.15 B3LYP/6-31G(d,p) 0.1 -0.9 -5.4 1.4 -4.4 
-x, -y, -z 4.64 B3LYP/6-31G(d,p) -6.1 -1.5 -21.5 7.2 -21.8 
- 7.86 B3LYP/6-31G(d,p) -23.0 -5.2 -13.9 23.3 -25.8 
-x, -y, -z 9.24 B3LYP/6-31G(d,p) 0.2 -0.2 -4.4 1.2 -3.0 
- 6.48 B3LYP/6-31G(d,p) -0.7 -1.9 -15.6 8.3 -10.7 
x, y, z 9.81 B3LYP/6-31G(d,p) 4.2 -0.5 -6.7 2.7 -0.2 
x, y, z 7.48 B3LYP/6-31G(d,p) -6.2 -4.1 -17.6 12.4 -17.2 
-x, -y, -z 5.95 B3LYP/6-31G(d,p) -19.3 -3.3 -65.1 48.2 -49.7 
-x, -y, -z 10.08 B3LYP/6-31G(d,p) -4.4 -0.5 -7.1 0.3 -11.1 
x, y, z 8.15 B3LYP/6-31G(d,p) -28.5 -10.8 -25.0 34.8 -38.3 
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- 6.95 B3LYP/6-31G(d,p) -27.0 -7.4 -13.2 19.9 -33.3 
- 6.48 B3LYP/6-31G(d,p) -0.7 -1.9 -15.6 8.3 -10.7 
-x, -y, -z 6.70 B3LYP/6-31G(d,p) -83.4 -15.0 -32.1 103.9 -63.1 
- 7.86 B3LYP/6-31G(d,p) -23.0 -5.2 -13.9 23.3 -25.8 
- 8.09 B3LYP/6-31G(d,p) 0.7 -1.4 -15.4 12.3 -6.1 
- 7.65 B3LYP/6-31G(d,p) 2.2 -2.6 -6.1 3.5 -2.8 
- 7.21 B3LYP/6-31G(d,p) 3.6 -1.9 -11.6 6.3 -3.8 
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